

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28888 A2

(51) International Patent Classification*: C07K 7/04,
A61K 39/095, G01N 33/68, C12N 15/11, 5/20

[NL/BE]; GlaxoSmithKline Biologicals s.a. Rue de l'Institut 89, B-1330 Rixensart (BE). VOET, Pierre [BE/BE]; GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart (BE).

(21) International Application Number: PCT/EP01/11409

(74) Agent: LUBIENSKI, Michael, John; Corporate Intellectual Property, GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 3 October 2001 (03.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0024200.8 3 October 2000 (03.10.2000) GB

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SL, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM BIOLOGICAL S.A.
[BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(84) Designated States (regional): AR IPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): DE BOLLE, Xavier, Thomas [BE/BE]; Laboratoire d'Immunologie et Microbiologie URB, Facultés Universitaires Notre Dame de la Paix, 61, rue de Bruxelles, B-5000 Namur (BE). LETESSON, Jean-Jacques [BE/BE]; Laboratoire d'Immunologie et Microbiologie URB, Facultés Universitaires Notre Dame de la Paix, 61, rue de Bruxelles, B-5000 Namur (BE). LOBET, Yves [BE/BE]; GlaxoSmithKline Biologicals s.a., Rue de l'Institut 89, B-1330 Rixensart (BE). MERTENS, Pascal, Yvon [BE/BE]; Laboratoire d'Immunologie et Microbiologie URB, Facultés Universitaires Notre Dame de la Paix, 61, rue de Bruxelles, B-5000 Namur (BE). POOLMAN, Jan



WO 02/28888 A2

(54) Title: COMPONENT FOR VACCINE

(57) Abstract: The present invention relates to a component for a vaccine against meningococci, in particular peptides which mimic epitopes of meningococcal lipoooligosaccharide, and to a vaccine comprising such a component.

1
COMPONENT FOR VACCINE

FIELD OF THE INVENTION

The present invention relates to a component for a vaccine against 5 meningococci, preferably peptides which mimic epitopes of meningococcal lipooligosaccharide, and to a vaccine comprising such a component.

BACKGROUND TO THE INVENTION

Neisseria meningitidis (meningococcus) is a Gram negative bacterium frequently 10 isolated from the human upper respiratory tract. It is a cause of serious invasive bacterial diseases such as bacteremia and meningitis. The incidence of meningococcal disease shows geographical, seasonal and annual differences (Schwartz, B., Moore, P.S., Broome, C.V.; Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). The bacterium is commonly classified according to the serogroup if its capsular polysaccharide.

15 Most disease in temperate countries is due to strains of serogroup B and varies in incidence from 1-10/100,000/year total population - sometimes reaching higher values (Kaczmarski, E.B. (1997), Commun. Dis. Rep. Rev. 7: R55-9, 1995; Scholten, R.J.P.M., Bijlmer, H.A., Poolman, J.T. et al. Clin. Infect. Dis. 16: 237-246, 1993; Cruz, C., Pavez, G., Aguilar, E., et al. Epidemiol. Infect. 105: 119-126, 1990).

20 Epidemics dominated by serogroup A meningococci, mostly in central Africa, sometimes reach incidence levels of up to 1000/100,000/year (Schwartz, B., Moore, P.S., Broome, C.V. Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Nearly all cases as a whole of meningococcal disease are caused by serogroup A, B, C, W-135 and Y meningococci, and a tetravalent A, C, W-135, Y capsular polysaccharide vaccine is 25 available (Armand, J., Arminjon, F., Mynard, M.C., Lafaix, C., J. Biol. Stand. 10: 335-339, 1982).

30 The frequency of *Neisseria meningitidis* infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiple antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Neisseria meningitidis* strains that are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.

The available polysaccharide vaccines are currently being improved by way of chemically conjugating them to carrier proteins (Lieberman, J.M., Chiu, S.S., Wong, V.K., et al. *JAMA* 275 : 1499-1503, 1996).

5 A serogroup B vaccine, however, is not available. The serogroup B capsular polysaccharide has been found to be ~~nonimmunogenic~~ - most likely because it shares structural similarity with host components (Wyle, F.A., Artenstein, M.S., Brandt, M.L. et al. *J. Infect. Dis.* 126: 514-522, 1972; Finne, J.M., Leinonen, M., Mäkelä, P.M. *Lancet* ii.: 355-357, 1983). Effort has therefore been focused in trying to develop serotype B vaccines from outer membrane vesicles or purified protein components therefrom.

10 Alternative meningococcal antigens for vaccine development are meningococcal lipooligosaccharides (LOS). These are outer membrane bound glycolipids which differ from the lipopolysaccharides (LPS) of the Enterobacteriaceae by lacking the O side chains, and thus resemble the rough form of LPS (Griffiss et al. *Rev Infect Dis* 1988; 10: S287-295). Heterogeneity within the oligosaccharide moiety of the LOS generates 15 structural and antigenic diversity among different meningococcal strains (Griffiss et al. *Inf. Immun.* 1987; 55: 1792-1800). This has been used to subdivide the strains into 12 immunotypes. Immunotypes L3, L7, L9 have an identical carbohydrate structure and have therefore been designated L3,7,9. Meningococcal LOS L3,7,9, L2 and L5 can be modified by sialylation, or by the addition of cytidine 5'-monophosphate-N- 20 acetylneuraminic acid. Antibodies to LOS have been shown to protect in experimental rats against infection and to contribute to the bactericidal activity in children infected with *N. meningitidis* (Griffiss et al *J Infect Dis* 1984; 150: 71-79).

25 The toxic component of the LOS, as in the case of endotoxin from other Gram-negative bacteria, lies in the lipid A moiety of the molecule, and not in the immunogenic oligosaccharide portion. Although it may be possible to separate the toxic part from the immunogenic portion of the molecule, once done the native conformation of the molecule may not be retained.

30 A solution to this difficulty is the identification of mimotopes which can mimic epitopes on the oligosaccharide moiety of the LOS. In this way surrogate antigens may be generated.

Peptides mimicking polysaccharides have been reported. For instance, mimotopes of meningococcal group B capsular polysaccharide (Moe et al. 1999. *FEMS Immunology and Medical Microbiology* 26: 209-226) and meningococcal group C capsular polysaccharide (Westerink et al. 1995 *Proc. Natl. Acad. Sci. USA*

92: 4021-4025) have been identified. Furthermore, WO 00/25814 discloses several serogroup B LOS L3,7,9 heptapeptide mimotopes.

As mimotopes can vary widely in their suitability for inclusion in a vaccine (that is whether they constitute an immunogenic mimotope which can induce a protective humoral immune response against the carbohydrate), there remains a need 5 to identify further classes of peptide mimotopes of meningococcal (particularly serogroup B) LOS.

10 SUMMARY OF THE INVENTION

To achieve the identification of further peptide mimotopes mimicking surface-exposed epitopes of *N. meningitidis* LOS, the present inventors have screened two phage-displayed random peptide libraries with five monoclonal antibodies directed against *N. meningitidis* LOS.

15 The present invention provides a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, said mimotope being antigenically cross-reactive with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78.

20 The present invention further provides a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, said mimotope comprising a peptide epitope obtainable by screening a peptide library with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78.

Vaccine compositions comprising the above mimotopes are also provided.

25 A further aspect of the invention relates to a vaccine against serogroup B, C, Y, or W-135 meningococci, which comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis* and a mimotope of a surface L2 LOS of *N. meningitidis*.

A still further aspect relates to a vaccine against serogroup A meningococci, which comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis* and a mimotope of a surface L10 LOS of *N. meningitidis*.

30

DETAILED DESCRIPTION OF THE INVENTION

The present invention aims to provide further classes of *N. meningitidis* LOS mimotopes for use as a component of a meningococcal vaccine.

The present invention provides a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, said mimotope being antigenically cross-reactive with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78. These monoclonal antibodies are each described later and are termed the

5 'mAbs of the invention'. These mAbs have high specificity and/or affinity to the L3,7,9 LOS. The meaning of mimotope is defined as an entity which is sufficiently similar to a native meningococcal LOS epitope so as to be capable of being bound by antibodies which recognise the native meningococcal LOS epitope. 'Antigenically cross-reactive' for the purposes of this invention means that the mimotope tests
10 positive in an ELISA test (preferably as performed in Example 3) or immunoblot on recombinant phages expressing the mimotope. Preferably, the mimotope does not have a naturally-occurring amino-acid sequence.

Preferably, the mimotopes of the invention can be used to immunise a host such that antibodies are produced which specifically cross-react with LOS, and
15 preferably cross-react with whole cell bacteria containing the LOS.

The present invention further provides a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, said mimotope comprising a peptide epitope obtainable by screening a peptide library with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78. Preferably, the mimotope does not
20 have a naturally-occurring amino-acid sequence.

Typically, the peptide epitope is obtainable by screening a peptide library (preferably a random, highly diverse one) with a monoclonal antibody of high specificity and/or affinity to the LOS. Typically techniques such as phage display technology (EP 0 552 267 B1) can be used for screening such libraries (preferably as
25 described in Example 2). This technique has the advantageous potential of allowing the identification of many peptide mimotopes so that a recognition pattern can be established in order to define essential features (or chemical properties) of an epitope contained within a peptide mimotope of L3,7,9 LOS.

In the present invention, a nonamer peptide library (either linear or disulfide-constrained, for instance as previously described by Felici et al. [1993 *Gene* 128: 21-27] and Luzzago et al. [1993 *Gene* 128: 51-57]) was found to be conveniently used to challenge the mAbs of the invention in order to identify peptide epitopes contained within the peptide mimotopes of SEQ ID NO: 1-140, 289-296 that were isolated from the libraries. Thus the mimotope of the invention preferably comprises a peptide

epitope contained within any one of the peptides of SEQ ID NO: 1-140, 289-296, or retro sequences thereof.

According to the present invention, the peptide epitope may comprise a sub-sequence of any one of SEQ ID NO:1-140, 289-296, or retro-sequences thereof, or 5 may be present in a longer peptide incorporating any one of SEQ ID NO:1-140, 289-296 (or retro-sequences thereof) or sub-sequences therefrom. Accordingly, the mimotopes of the present invention may consist of addition of N and/or C terminal extensions of a number of other natural residues at one or both ends of the peptides of SEQ ID NO:1-140, 289-296.

10 Preferably the mimotope of the invention comprises any one of the peptides of SEQ ID NO: 1-140, 289-296 (the peptides of the invention), or retro sequences thereof, or modifications of the peptides or retro sequences. Most preferably, the mimotopes comprising the retro sequences and modifications of the peptides of the invention should retain cross-reactivity with a monoclonal antibody selected from a 15 group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78. Most preferably, the mimotope of the invention comprises any one of the peptides of SEQ ID NO:153, 154, 157, 162, 167, 168, 169, 170, 179, 45, 47, 190, 191, 53, 194, 55, 58, 61, 63, 206, 75, 222, 83, 85, 86, 227, 88, 93, 243, 104, 245, 255, 124, 271, 272, 273, 279, 280, 297, 298, 291, 292, 293, 294, 295, and 296 (corresponding, respectively, to peptide No. 13, 14, 17, 22, 27, 28, 29, 30, 39, 45, 47, 50, 51, 53, 54, 55, 58, 61, 63, 66, 75, 82, 83, 85, 86, 87, 88, 93, 103, 104, 105, 115, 124, 131, 132, 133, 139, 140, 141, 142, 143, 144, 145, 146, 147, and 148 with reference to Table 2 in Example 2) or 20 retro sequences and modifications of the peptides which are still recognised by one or more mAbs in the ELISA test of Example 3.

25 By 'retro sequences' with reference to a peptide sequence it is meant peptide sequences where the sequence orientation is reversed. Thus a retro sequence of the peptide AGDT is TDGA. It has been found in the art that retro sequences of peptide mimotopes are often peptide mimotopes themselves. Peptide mimotope sequences of the invention may be entirely or at least in part comprised of D-stereo isomer amino 30 acids (inverso sequences). Also, the peptide sequences may be retro-inverso in character, in that the sequence orientation is reversed and the amino acids are of the D-stereoisomer form. Such retro, inverso or retro-inverso peptides have the advantage of potentially being more stable and/or immunogenic in a host when administered as an immunogen. Methods to make D amino acids and incorporate them into proteins

are well known in the art [see, for example, Thorson *et al.* (1998) *Methods Mol. Biol.* 77:43-73, & Chartrain *et al.* (2000) *Curr. Opin. Biotechnol.* 11:209-14].

Peptide mimotopes comprising the peptides of the invention may be modified (modifications of the peptides of the invention) for a particular purpose by addition, deletion or substitution of elected amino acids.

For example, 1, 2, 3, 4, 5, 6, 7, 8 or 9 amino acids of each of the peptides of SEQ ID NO:1-140, 289-296 can be replaced by the amino acid that most closely resembles that amino acid. For example, A may be substituted by V, L or I, as described in the following table.

Original residue	Exemplary substitutions	Preferred substitution
A	V, L, I	V
R	K, Q, N	K
N	Q, H, K, R	Q
D	E	E
C	S	S
Q	N	N
E	D	D
G	P, A	A
H	N, Q, K, R	R
I	L, V, M, A, F	L
L	I, V, M, A, F	I
K	R, Q, N	R
M	L, F, I	L
F	L, V, I, A, Y	L
P	A	A
S	T	T
T	S	S
W	Y, F	Y
Y	W, F, T, S	F
V	I, L, M, F, A	L

10

Furthermore, the peptides of the present invention may be modified for the purposes of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine to the peptide. In addition it may be desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. This reduces the conformational degrees of freedom of the peptide, and thus increases the probability that the peptide is presented in a conformation which most

15

closely resembles that of the L3,7,9 LOS epitope in the context of the whole molecule. For example, the peptides may be modified to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to enhance stability of the peptide. Those skilled in the art will realise that such modified peptides, or mimotopes, could be a wholly or partly non-peptide mimotope wherein the constituent residues are not necessarily confined to the 20 naturally occurring amino acids. Furthermore, one or more amino acids may be deleted from the peptides of the invention, as long as an epitope is retained which is capable of cross-reacting with the monoclonal antibodies of the invention. Typically such an epitope would have at least 4, 5, 6, 7 or 8 amino acids. In addition, the peptides of the invention may be cyclised by techniques known in the art to constrain the peptide into a conformation that closely resembles its shape when the peptide sequence is in the context of the whole LOS molecule.

15 Thus in a preferred further embodiment, the mimotope may comprise an oligopeptide which is structurally more constrained than a linear form of the oligopeptide. It is thought that peptides which assume fewer conformations or which have their conformations locked are more likely to elicit an immune response because they present to the binding portion of antibodies a structurally constrained epitope.

20 Substituents such as covalent linkages to further peptide chains or intramolecular linkages will structurally constrain the oligopeptide. For example, the oligopeptide may form part of the primary structure of a larger polypeptide containing the amino acid sequence of the oligopeptide. Preferably, the oligopeptide comprises a cyclic peptide, as discussed in further detail below.

25 Other substituents include covalent linkages to other moieties such as macromolecular structures including biological and non-biological structures. Examples of biological structures include carrier proteins such as those described below for enhancing the immunogenicity of the mimotope. Examples of non-biological structures include lipid vesicles such as micelles and the like.

30 In a preferred embodiment, the oligopeptide comprises a cyclic peptide. Use of a cyclic peptide. Typically, the cyclic peptide comprises a cyclised portion, which cyclised portion preferably comprises an amino acid sequence, the terminal amino acids of which are linked together by a covalent bond. The covalent bond is conveniently a disulphide bridge, such as found between cysteine residues. The

cyclised portion typically comprises a nonapeptide and this nonapeptide can conveniently form part of the amino acid sequence which is flanked by the amino acids which are linked by the covalent bond to form the cyclised portion.

5 Examples of preferred cyclised peptides which contain a pair of cysteine residues to allow the formation of a disulphide bridge are SEQ ID NO:141-280, 297-301 (and retro, inverso, or retroinverso variants thereof, as defined above).

As described above, the large number of peptide mimotopes identified by the phage display technique allows the identification of patterns which define an epitope (or part of an epitope) of a mimotope of L3,7,9 LOS. Accordingly a further aspect of 10 the invention is peptide mimotopes of L3,7,9 LOS comprising the amino acid sequence (either linear or cyclised): WY; PP; AP; PY; PPY; PPF; PPW; APP; WYS; WYT; LWY; GGY; GPY; PPYD (a preferred motif); PPFD; FDPD; GGYL; PPWD; SLWY; PXWY; WYXXP; YXY; PWST; EKKXF or WXY (where each X is the same or different and is an amino acid, preferably a naturally-occurring amino acid).

15 In a preferred embodiment, the peptides incorporating the above identified epitopes or peptidic mimotopes of the present invention will be of a small size. It is envisaged that peptidic mimotopes, therefore, should be less than 100 amino acids in length, preferably shorter than 75 amino acids, more preferably less than 50 amino acids, and most preferable within the range of 4 to 25 amino acids long. In a specific 20 embodiment the peptide is 9 amino acids in length.

It will be apparent to the man skilled in the art that techniques may be used to 25 confirm the status of a specific construct as a mimotope suitable for use in a vaccine against meningococcus. Such techniques include the following: the putative mimotope can be assayed to ascertain the immunogenicity of the construct, in that antisera raised by the putative mimotope cross-react with the native L3,7,9 LOS molecule, and are also functional in bactericidal assays against *N. meningitidis* of the L3,7,9 immunotype. Typically bactericidal assays are performed as described in Example 1.4. They may also be done using standard opsonophagocytosis experiments in an animal model such as the infant rat.

30 In one embodiment of the present invention at least one peptide as hereinbefore described, incorporating a peptide epitope or mimotope, is linked to carrier molecules to form immunogens for vaccination protocols. The peptides may be linked via chemical covalent conjugation or by expression of genetically engineered fusion partners, optionally via a linker sequence.

The covalent coupling of the peptide to the immunogenic carrier can be carried out in a manner well known in the art. Thus, for example, for direct covalent coupling it is possible to utilise a carbodiimide, glutaraldehyde or (N-[γ -maleimidobutyryloxy]) succinimide ester, utilising common commercially available 5 heterobifunctional linkers such as CDAP and SPDP (using manufacturers instructions). After the coupling reaction, the immunogen can easily be isolated and purified by means of a dialysis method, a gel filtration method, a fractionation method etc.

The types of carriers used in the immunogens of the present invention will be 10 readily known to the man skilled in the art. The function of the carrier is to provide cytokine help in order to help induce an immune response against the peptide of the invention. A non-exhaustive list of carriers which may be used in the present invention include: Keyhole limpet Haemocyanin (KLH), serum albumins such as bovine serum albumin (BSA), inactivated bacterial toxins such as tetanus or diphtheria 15 toxins (TT and DT), or recombinant fragments thereof (for example, Domain 1 of Fragment C of TT, or the translocation domain of DT), CRM197, or the purified protein derivative of tuberculin (PPD). Alternatively the mimotopes or epitopes may be directly conjugated to liposome carriers, which may additionally comprise immunogens capable of providing T-cell help. Preferably the ratio of peptides to 20 carrier is in the order of 1:1 to 20:1, and preferably each carrier should carry between 3-15 peptides.

In an embodiment of the invention a preferred carrier is Protein D (an IgD-binding protein) from *Haemophilus influenzae* (WO 91/18926, EP 0 594 610 B1). In some circumstances, for example in recombinant immunogen expression systems it 25 may be desirable to use fragments of protein D, for example Protein D 1/3rd (comprising the N-terminal 100-110 amino acids of protein D (WO 99/10375)).

Another preferred method of presenting the peptides of the present invention is 30 in the context of a recombinant fusion molecule. For example, EP 0 421 635 B describes the use of chimeric hepatitis B core antigen particles to present foreign peptide sequences in a virus-like particle. As such, immunogens of the present invention may comprise peptides presented in chimeric particles consisting of hepatitis B core antigen. Additionally, the recombinant fusion proteins may comprise

the mimotopes of the present invention and a carrier protein, such as NS1 of the influenza virus.

Alternatively, the peptides of the present invention could be inserted within or substitute a surface-exposed loop of an outer membrane protein (preferably of meningococcal origin, for example PorA, PorB, PilC, TbpA, FrpB or LbpA). This has the advantage of constraining the peptide into a shape that can mimic the LOS epitope. Additionally, this may be advantageous in terms of administering the immunogen to a host in an outer membrane vesicle preparation (or bleb preparation) from a meningococcal strain expressing the immunogen. Such an improved bleb preparation is a further aspect of the invention.

For any recombinantly expressed protein which forms part of the present invention, a nucleic acid sequence which encodes said immunogen also forms an aspect of the present invention. Additionally, DNA sequences encoding any aforementioned peptide or mimotope of the present invention are further aspects.

DNA molecules, for instance plasmids, comprising the DNA sequences of the present invention may be used as an immunogen in the manner described by Kieber-Emmons et al. (Journal of Immunology 2000 165:623-627). Such a strategy may advantageously trigger a cross-reactive Th1 immune response against the LOS in the host. A vaccine comprising such DNA molecules, and the use of such a vaccine for the treatment or prevention of meningococcal disease are further aspects of the invention.

Peptides used in the present invention can be readily synthesised by solid phase procedures well known in the art. Suitable syntheses may be performed by utilising "T-boc" or "F-moc" procedures. Cyclic peptides can be synthesised by the solid phase procedure employing the well-known "F-moc" procedure and polyamide resin in the fully automated apparatus. Alternatively, those skilled in the art will know the necessary laboratory procedures to perform the process manually. Techniques and procedures for solid phase synthesis are described in 'Solid Phase Peptide Synthesis: A Practical Approach' by E. Atherton and R.C. Sheppard, published by IRL at Oxford University Press (1989). Alternatively, the peptides may be produced by recombinant methods, including expressing nucleic acid molecules encoding the mimotopes in a bacterial or mammalian cell line, followed by purification of the expressed mimotope. Techniques for recombinant expression of peptides and proteins are known in the art, and are described in Maniatis, T., Fritsch, E.F. and Sambrook et al., *Molecular*

cloning, a laboratory manual, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989).

The monoclonal antibodies of the invention, and pharmaceutical compositions comprising them, form part of the present invention. These antibodies (H44/24, 5 H44/58, H44/70, H44/78 and 4BE12C10) are capable of being used in passive prophylaxis or therapy, by administration of the antibodies into a patient, for the amelioration or prevention of meningococcal disease. These antibodies are preferably made from a hybridoma. The H44/24, H44/58, H44/70 and H44/78 hybridomas of the invention have been deposited as Budapest Treaty patent deposit at ECACC 10 (European Collection of Cell Cultures, Vaccine Research and Production Laboratory, Public Health Laboratory Service, Centre for Applied Microbiology Research, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK) on 22/9/00 under Provisional Accession No. 92209, 92210, 92211, and 92212, respectively. The antibodies produced by these hybridomas are further defined by the DNA sequence which encodes their light and 15 heavy chains as recited in SEQ ID NO:281-288. The 4BE12C10 antibody can be obtained from the National Institute of Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3QG, UK. The antibodies may be humanised or CDR grafted for therapeutic use using the sequences of SEQ ID NO:281-288 and techniques known in the art [see, for example, Holliger and Bohlen 20 (1999) Cancer Metastasis Rev. 18:411-9, Gavilondo and Larrick (2000) Biotechniques 29:128-32, 134-6, 138, and Kipriyanov and Little (1999) Mol. Biotechnol. 12:173-201]. The term "antibody" herein is used to refer to a molecule having a useful antigen binding specificity. Those skilled in the art will readily appreciate that this term may also cover polypeptides which are fragments of the 25 monoclonal antibodies of the invention which can show the same or a closely similar functionality. Such antibody fragments or derivatives are intended to be encompassed by the term antibody as used herein.

Mimotopes of L3,7,9 LOS that are capable of binding to the monoclonal antibodies of the invention, and immunogens comprising these mimotopes, form an 30 important aspect of the present invention. Vaccines comprising mimotopes that are capable of binding to these antibodies are useful in the treatment or prevention of meningococcal disease.

Also forming an important aspect of the present invention is the use of the monoclonal antibodies of the invention in the identification of novel mimotopes of meningococcal L3,7,9 LOS, for subsequent use as an immunogen.

The present invention provides the use of novel peptides encompassing the epitopes or mimotopes of the present invention (as defined above), in the manufacture of pharmaceutical compositions for the prophylaxis or therapy of meningococcal disease. Immunogens comprising the mimotope or peptide of the present invention and a carrier molecule are also provided for use in vaccines for the immunoprophylaxis or therapy of meningococcal disease. Accordingly, the 10 mimotopes, peptides or immunogens of the present invention are provided for use in a medicament, and in the medical treatment or prophylaxis of meningococcal disease. Accordingly, there is provided a method of treatment of meningococcal disease comprising the administration to a patient suffering from or susceptible to said disease, of a vaccine or medicament of the present invention.

15 Vaccines of the present invention may also include suitable excipients or diluents. Advantageously, an adjuvant is also included. Suitable adjuvants for vaccines of the present invention comprise those adjuvants that are capable of enhancing the antibody responses against the immunogen. Adjuvants are well known in the art (Vaccine Design – The Subunit and Adjuvant Approach, 1995, 20 Pharmaceutical Biotechnology, Volume 6, Eds. Powell, M.F., and Newman, M.J., Plenum Press, New York and London, ISBN 0-306-44867-X). Preferred adjuvants for use with immunogens of the present invention include aluminium or calcium salts (for example hydroxide or phosphate salts). Other adjuvants include saponin adjuvants such as QS21 (US 5,057,540) and 3D-MPL (GB 2220 211).

25 The vaccines of the present invention will be generally administered for both priming and boosting doses. It is expected that the boosting doses will be adequately spaced, or preferably given yearly or at such times where the levels of circulating antibody fall below a desired level. Boosting doses may consist of the peptide in the absence of the original carrier molecule. Such booster constructs may comprise an 30 alternative carrier or may be in the absence of any carrier.

The vaccine preparation of the present invention may be used to protect or treat a mammal susceptible to, or suffering from meningococcal disease, by means of administering said vaccine via systemic or mucosal route. These administrations may include injection *via* the intramuscular, intraperitoneal, intradermal, transdermal or

subcutaneous routes; or *via* mucosal administration to the oral/alimentary, respiratory, genitourinary tracts.

The amount of protein, peptide(s) or conjugated peptide(s) in each vaccine dose is selected as an amount which induces an immunoprotective response without 5 significant, adverse side effects in typical vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 µg of protein/peptide, preferably 1-500 µg, preferably 1-100 µg, of which 1 to 50µg is the most preferable range. An optimal amount for a particular vaccine can be ascertained by standard 10 studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisations adequately spaced.

Aspects of the present invention may also be used in diagnostic assays. For example, the peptides or mimotopes of the present invention could be used to detect 15 antibodies against L3,7,9 in the serum of a patient. Likewise the monoclonal antibodies of the invention could be used for detecting the presence of L3,7,9 immunotype meningococcus in a sample from a patient.

Vaccine preparation is generally described in *New Trends and Developments in Vaccines*, edited by Voller et al., University Park Press, Baltimore, Maryland, 20 U.S.A. 1978. Conjugation of proteins to macromolecules is disclosed by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4, 474,757.

An independent aspect of the invention is a vaccine against serogroup B, C, Y, or W-135 meningococci, which comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis* and a mimotope of a surface L2 LOS of *N. meningitidis*. Optionally, this vaccine may advantageously also comprise one or more plain or conjugated meningococcal capsular polysaccharides selected from a group comprising: C, Y and W-135.

A further aspect is a vaccine against serogroup A meningococci, which 30 comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis* and a mimotope of a surface L10 LOS of *N. meningitidis*. Optionally, this vaccine may advantageously also comprise plain or conjugated *N. meningitidis* serogroup A capsular polysaccharide.

A further aspect still is a vaccine against serogroup A, B, C, Y, or W-135 meningococci, which comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, a mimotope of a surface L10 LOS of *N. meningitidis* and a mimotope of a surface L2 LOS of *N. meningitidis*. Optionally, this vaccine may advantageously 5 also comprise one or more plain or conjugated meningococcal capsular polysaccharides selected from a group comprising: A, C, Y and W-135.

The inventors have found that the above formulations prove extremely effective in the immunoprotection of a mammalian host against the majority of strain variants encompassed within the above mentioned groups of meningococcal 10 serotypes. Preferably, the mimotopes of the invention can be used to immunise a host such that antibodies are produced which specifically cross-react with LOS, and preferably cross-react with whole cell bacteria containing the LOS.

Each mimotope may be either peptidic or non-peptidic. Non-peptidic mimotopes are envisaged to be of a similar size, in terms of molecular volume, to their peptidic counterparts. Preferably, the mimotopes are antigenically cross-reactive 15 with a monoclonal antibody of high specificity and/or affinity to the respective surface LOS. Preferably one or both mimotopes in the above vaccine combinations comprise a peptide epitope.

The peptide epitopes may be obtainable by screening a peptide library with a 20 monoclonal antibody specific (and/or of high affinity) to the respective surface LOS. For the purposes of this invention, 'high affinity' typically means having an affinity constant of at least 10^5M^{-1} , preferably a least 10^6M^{-1} .

Monoclonal antibodies of high specificity and/or affinity to LOS may be prepared using outer membrane complexes as immunogens and detecting antigens 25 according to established protocols (see for example Zollinger *et al.* 1983. I&I 40:257-264; Adbillahi *et al.* 1988. Microbial Pathogenesis 4:27-32).

The mimotope preferably comprises a peptide epitope which may be identified 30 by screening a peptide library with the monoclonal antibody. Typically, a peptide library such as a heptapeptide or a nonapeptide (see above) library preferably containing all possible amino acid sequences should be used to give the greatest diversity of potential epitopes against which antigenic cross-reactivity with the monoclonal antibody can be assessed. Typically, a random peptide library of this nature is used.

Preferably the mimotopes are obtainable using cross-reactivity with the following monoclonal antibodies as a selection means: H44/24, H44/58, H44/70, H44/78, 4BE12C10, 4A8-B2 or 9-2-L397 for L3,7,9 LOS mimotopes; F1-5H 5/ID9 for L2 LOS mimotopes; and 5B4-F9-B10 for L10 LOS mimotopes.

5 H44/24, H44/58, H44/70, H44/78, and 4BE12C10 antibodies are described above. 4A8-B2, 9-2-L397, F1-5H 5/ID9 and 5B4-F9-B10 monoclonal antibodies may be obtained from the National Institute of Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Herts, EN6 3QG, UK and may also be obtained through ECACC.

10 The peptide mimotopes of the above formulations may be conformationally constrained as described above. The mimotopes of each respective formulation may be contained within a single molecule. They may be linked to the same or different carrier molecules as described above. For instance they may be inserted within or substitute the same or different exposed loop region(s) of the same outer membrane 15 protein of meningococcus (as described above).

The L3,7,9 mimotopes used in the formulations are preferably the mimotopes and peptides of the invention described above. Alternatively the mimotope of the L3,7,9 LOS can comprises a peptide disclosed in WO 00/25814, preferably selected from: IHRQGIH; HIGQRHI; LPARTEG; GETRAPL; APARQLP; PLQRAPA; 20 KQAPVHH; HHVPAQK; LQAPVHH; HHVPAQL; LPSIQLP; PLQISPL; NELPHKL; LKHPLEN; KSPSMTL; LTMSPSK; AGPLMLL; LLMLPGA; WSPILLD DLLIPSW; LSMHPQN; NQPHMSL; HSMHPQN NQPHMSH; SMYGSYN; NYSGYMS; TNHSLYH; HYLSHNT; HAIYPRH; HRPYIAH; TTYSRFP; PFRSYTT; TDSLRL; LLRLSDT; SFATNIP; and PINTAFS.

25 A preferred embodiment of the invention is a global vaccine which is particularly beneficial in the treatment or prevention of meningococcal disease comprising a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, a mimotope of a surface L10 LOS of *N. meningitidis*, and a mimotope of a surface L2 LOS of *N. meningitidis*; optionally also comprising one or more plain or conjugated 30 meningococcal capsular polysaccharides selected from a group comprising: A, C, Y and W-135.

A further preferred embodiment of the invention is a global vaccine which is particularly beneficial in the treatment or prevention of meningitis comprising the vaccine combinations described above (preferably that containing L3,7,9, L2 and L10

peptide mimotopes, and optionally one or more meningococcal capsular polysaccharides), and one or more plain or conjugated pneumococcal capsular polysaccharide antigens. The pneumococcal capsular polysaccharide antigens are preferably selected from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 5 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F (most preferably from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).

Yet another preferred combination of the invention is a global vaccine which is particularly beneficial in the treatment or prevention of meningitis comprising one or more (2 or 3) peptide mimotopes from the list consisting of L3,7,9, L2 and L10, 10 and a conjugated *H. influenzae* b capsular polysaccharide.

The above vaccine combinations are suitable for use as a medicament, and may be used in the manufacture of a medicament for the treatment or prevention of meningococcal disease. A method for treating a patient suffering from or susceptible to meningococcal disease, comprising the administration of the above vaccine 15 combinations to the patient is a further aspect of the invention.

EXAMPLES

The examples below were carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described 5 in detail. The examples are illustrative, but do not limit the invention.

Example 1: Monoclonal antibodies directed against *N. meningitidis* L3,7,9 LOS**1.1 Isolation and functional characterization of the monoclonal antibodies**

10

Immunization

Neisseria meningitidis B cells (heat inactivated cells from the H44/76 isolate, B:15:P1.7, 16, Los 3,7,9) were injected three times in BALB/C mice on days 0, 21 and 42 (5 animals/group). Cells, formulated in an oil-in-water/3D-MPL/QS21 15 adjuvant (as described in WO 95/17210), were injected both by the subcutaneous and intraperitoneal routes. Animals were evaluated 7 days after the third injection for antibody response in a whole cell Elisa.

Fusion procedure to obtain specific hybridoma cell lines

20

On days -10 and -7 before fusion, Sp2/0 Ag 14 myeloma cells were thawed and cultivated in a flask in order to reach and maintain a 10^5 cells/ml culture up to the fusion day (day 0). On day -1, myeloma cell concentration was adjusted to 10^5 cells/ml. At the same time, plates of feeder cells using peritoneal macrophages were prepared (10^5 macrophages/ml; 100 μ l/well).

25

On day 0, the spleen of the selected mouse was taken (under sterile conditions) and perfused with 10 to 20 ml of DMEM medium inside a Petri dish. Cells were counted (using a Sysmex counter and 2 drops of "Quicklyser" to lyse red cells) and centrifuged for 10 min. at 150-200 g (1000 rpm using the Beckman GPR centrifuge). Sp2/0 and spleen cells were washed, counted and centrifuged for 10 min at 150-200 g 30 before mixing in a 1:5 ratio (Sp2/0 : spleen cells). The 1:5 mixing ratio was done in 25 ml DMEM and centrifuged for 5 min at 400 g (1500 rpm using the GPR centrifuge, 50-ml Falcon tube). The supernatant was discarded and the tube slightly tapped to put the pellet in suspension. The cells were kept as much as possible at 37°C, in a water-

bath. One ml of PEG solution (PEG 4000 at 40 % v/v with 5 % de DMSO at pH 8.0-8.2), kept at 37°C, was slightly added (drop by drop) within 1 minute, while the tube was slightly shaken. The temperature of the cells had to be as close as possible to 37°C. From this PEG step, cells were manipulated gently. After 30 sec to 1 min, 1 ml 5 of DMEM was added within 1 min, then 2 ml of DMEM within 2 min., and 4 ml DMEM within 4 min.. Finally, the tube was filled with DMEM + additives in order to reach a volume of about 20 ml., and was centrifuged for 10 min. at 400 g.

10 Afterwards, the pellet was suspended gently in 15 to 25 ml of complete medium (DMEM, FCS + HS (Volker), HAT and Nutridoma) with a 25 ml pipet in order to break the aggregates.

Incubation of the tube was done for 2 h. at 37°C in a CO₂ incubator. The cells were then diluted to an adequate concentration (2.5 10⁴ to 10⁵ cells/well) and 100 µl of cells were plated in 96 wells microplates previously inoculated with feeder cells.

15 1.2 Recognition of cell surface epitopes by whole cell ELISA

The homologous H44/76 MenB strain (B:15:P1.7, 16) was used as coated bacteria to detect specific anti-*Neisseria meningitidis* antibodies in animal sera, as well as in supernatants of hybridoma cultures after splenocyte fusion. Briefly, microtiter plates (Maxisorp, Nunc) were coated with 100 µl of a 1/10 dilution (in 20 PBS) with a H44/76 bacteria solution from a 6 hours culture, in which bacteria were killed by 400 µg/ml tetracycline. Plates were incubated at 37°C for at least 16 hours until plates were completely dried. Then, they were washed three times with 300 µl of 150 mM NaCl - 0.05 % Tween 20. Afterwards, plates were overcoated with 100 µl of PBS-0.3 % casein and incubated for 30 min at room temperature 25 with shaking. Plates were washed again using the same procedure before incubation with antibodies. Animal sera were serially two-fold diluted in PBS-0.3 % Casein 0.05 % Tween 20 and put into the microplates (12 dilutions starting at the 1/100 dilution) before incubation at room temperature for 30 min with shaking, before the next identical washing step. For screening of the monoclonal antibodies, 30 supernatants were put as such (non diluted) in the microplates. Anti-mouse immunoglobulins (rabbit Ig, Dakopatts E0413) conjugated to biotin is used at 1/2000 in PBS - 0.3 % casein - 0.05 % Tween 20 to detect specific antibodies

against several antigens at the cell surface. After the last washing step (as before), plates were incubated with a streptavidin-peroxidase complex solution diluted at 1/4000 in the same solution for 30 min at room temperature under shaking conditions. For characterization of the mabs, a few other *Neisseria meningitidis* B 5 strains were also used as coated bacteria using the same procedure as described above: strains M97250 687 (B:4:P1.15) and M97252078 isolated in UK from human beings. Transformed H44/76D⁺ cells lacking the capsular polysaccharide and having a mutated LOS were also used by whole cell Elisa to characterize these mabs (see the next paragraph). Reactivity of the antibodies in whole cell ELISA ranged 10 from no detected signal (-) to strong reactivity (++) .

1.3 Strain transformation

The plasmid pMF121 (Frosch *et al.*, 1990) was used to construct a *Neisseria meningitidis* serogroup B strain lacking the capsular polysaccharide. This plasmid 15 contains the erythromycin resistance gene flanked by recombination regions corresponding to the ends of gene cluster encoding the group B polysaccharide (B PS) biosynthetic pathway. Deletion of the B PS resulted in loss of expression of the group B capsular polysaccharide as well as a deletion in the active copy of *galE* leading to the synthesis of galactose-deficient lipo-oligosaccharide (LOS).

20 *Neisseria meningitidis* serogroup B strain H44/76 (B:15:P1.7, 16; LOS 3,7,9) was used for transformation. After an overnight CO₂ incubation on Muller-Hinton (MH) plate (without erythromycin), cells were collected in liquid MH containing 10 mM MgCl₂ (2 ml were used per MH plate) and diluted up to an OD of 0.1 (550 nm). To this 2 ml solution, 4 µl of the plasmid pMF121 stock solution (0.5 µg/ml) were 25 added for a 6 hours incubation period at 37°C (with shaking). A control group was done with the same amount of *Neisseria meningitidis* bacteria, but without addition of plasmid. After the incubation period, 100 µl of culture, as such, at 1/10, 1/100 and 1/1000 dilutions, were put in MH plates containing 5, 10, 20, 40 or 80 µg erythromycin /ml before incubation for 48 hours at 37°C.

30

Colony blotting:

After plate incubation, transformants were selected and grown onto erythromycin/ MH plates (10 to 80 µg erythromycin/ml). The day after, all the visible

colonies were placed on new MH plates without erythromycin in order to let them grow. Then, they were transferred onto nitrocellulose sheets (colony blotting) and probed for the presence of B polysaccharide. Briefly, colonies were plotted onto a nitrocellulose sheet and rinsed directly in PBS-0.05 % Tween 20 before cell inactivation for 1 hour at 56°C in PBS-0.05% Tween 20 (diluant buffer). Afterwards, the membrane was overlaid for one hour in the diluant buffer at room temperature (RT). Then, membranes were washed again for three times 5 minutes in the diluant buffer before incubation with the anti-B PS 735 Mab (From Dr Frosch, via Boehringer) diluted at 1/3000 in the diluant buffer for 2 hours at RT. After a new washing step (3 times 5 minutes), the monoclonal antibody was detected with a biotinylated anti-mouse Ig from Amersham (RPN 1001) diluted 500 times in the diluant buffer (one hour at RT) before the next washing step (as described above). Afterwards, sheets were incubated for one hour at RT with a solution of streptavidin-peroxidase complex diluted 1/1000 in the diluant buffer. After the last three washing steps using the same method, nitrocellulose sheets were incubated for 15 min in the dark using the revelation solution (30 mg of 4-chloro-1-naphtol solution in 10 ml methanol plus 40 ml PBS and 30 mcl of H₂O₂ 37% from Merck). The reaction was stopped with a distilled water-washing step. Clones lacking reactivity with the anti-B PS Mab were further characterized by whole cell ELISA.

20

Whole cell ELISA:

Whole cell ELISAs were also done using the transformed colonies and the wild type strain (H44/76) as coated bacteria (20 µg protein/ml), and a set of different monoclonal antibodies used to characterize *Neisseria meningitidis* strains. The following Mabs were tested: anti-B PS (735 from Dr Frosch), and the other Mabs from the National Institute for Biological Standards and Control, London: anti-B PS (Ref 95/750) anti-P1.7 (A-PorA, Ref 4025), anti-P1.16 (A-PorA, Ref 95/720), anti-Los 3,7,9 (A-LPS, Ref 4047), anti-Los 8 (A-LPS, Ref 4048), and anti-P1.2 (A-PorA Ref 95/696).

30

Microtiter plates (Maxisorp, Nunc) were coated with 100 µl of the recombinant meningococcal B cells solution overnight (ON) at 37°C at around 20 µg/ml in PBS. Afterwards, plates are washed three times with 300 µl of 150 mM NaCl - 0.05 % Tween 20, and were overlaid with 100 µl of PBS-0.3 % Casein and incubated for 30 min at room temperature with shaking. Plates were washed again

using the same procedure before incubation with antibodies. Monoclonal antibodies (100 μ l) were used at different dilutions in PBS-0.3 % Casein 0.05 % Tween 20 and put onto the microplates before incubation at room temperature for 30 min with shaking, before the next identical washing step. 100 μ l of the anti-mouse Ig (from

5 rabbit, Dakopatts E0413) conjugated to biotin and diluted at 1/2000 in PBS-0.3 % Casein - 0.05 % Tween 20 were added to the wells to detect bound monoclonal antibodies. After the washing step (as before), plates were incubated with a streptavidin-peroxidase complex solution (100 μ l of the Amersham RPN 1051) diluted at 1/4000 in the same working solution for 30 min at room temperature under
10 shaking conditions. After this incubation and the last washing step, plates are incubated with 100 μ l of the chromogenic solution (4 mg orthophenylenediamine (OPD) in 10 ml 0.1 M citrate buffer pH4.5 with 5 μ l H₂O₂) for 15 min in the dark. Plates are then read at 490/620 nm using a spectrophotometer.

15 Routinely, about 10% of the transformants resulted from double cross-over. Bacterial clone H44/76D lacking reactivity against BPS & LOS but still reactive against P1.7 & P1.16 mAbs was selected for further studies.

1.4 Bactericidal assay

20 The bactericidal activity of these monoclonal antibodies was measured. Briefly, the *Neisseria meningitidis* serogroup B (H44/76 strain as a first strain) is used to determine the bactericidal activity of the antibodies (animal or human sera or monoclonal antibodies). In U-bottom 96 well microplates (NUNC), 50 μ l/well of serial two-fold serum dilutions were incubated with 37.5 μ l/well of the log phase
25 meningococcal suspension adjusted to $2.5 \cdot 10^4$ CFU/ml and incubated for 15 min at 37°C with shaking at 210 rpm (Orbital shaker, Forma Scientific). Then, 12.5 μ l of the baby rabbit complement (Pel-freeze Biologicals, US) is added before incubation for one more hour in the same conditions. Afterwards, 10 μ l aliquots of the mixture from each well were spot onto Mueller-Hinton agar plates containing 1% Isovitalex and 1%
30 of heat inactivated Horse serum before overnight incubation at 37°C with 5% CO₂. The day after, colonies are counted for each dilution tested and bactericidal titers determined as the dilution of the serum for 50 % killing, compared with the complement control without serum. By this method, individual colonies can be

counted up to 100 CFU per spot. Titers are expressed as the dilution which induce 50 % killing, calculated by regression analysis.

1.5 Results

5 Table 1 illustrates results obtained with 4 anti-LOS monoclonal antibodies from two fusion experiments with splenocytes from mice immunized with *Neisseria meningitidis* strain H44/76. The LOS specificity of the 4 monoclonal antibodies is supported by their failure to react with the H44/76D (BPS and LOS mutated) strain in whole cell ELISA, whereas these readily reacted with the wild type H44/76 strain.

10 Considering the non-immunogenic nature of the BPS, it is extremely unlikely that these monoclonal antibodies react with the capsular polysaccharide. All 4 monoclonal antibodies exhibited bactericidal activity against the wild type strain H44/76. Monoclonal antibodies H44/24 and H44/58 were shown to cross-react with M97250687 and M97252078 *N. meningitidis* strains by whole cell ELISA.

15

Table 1:

Antibody	Isotype	Bactericidal activity against strain H44/76 (titer)	Recognition of <i>N. meningitidis</i> strains by whole cell ELISA			
			H44/76 (wild type)	H44/76D (mutant)	M97250687	M97252078
H44/24	IgG3	>2560	+++	-	+++	+++
H44/58	IgG1	973	+++	-	+++	++
H44/70	IgM	1884	+++	-	NT	NT
H44/78	IgM	>2560	+++	-	NT	NT

NT. = not tested

20 1.6 Structural characterization of the 4 selected monoclonal antibodies

The primary structure of the monoclonal antibodies was determined by sequencing the cDNA encoding the variable heavy and light chains. To achieve this, total RNA was extracted from the hybridomas producing those 4 monoclonal antibodies. Sequencing has been carried out on RT-PCR products obtained following 25 PCR using primers specific for heavy or light chains.

Extraction of RNA from hybridomas

Extraction is performed on 10^6 cells as determined after counting in a Thoma cell. Cells are centrifuged 10 minutes at 1200RPM and supernatant is removed. Cells are centrifuged again 2 minutes at 1200RPM and all traces of supernatant are removed. Cells are resuspended in 200 μ l RNAse-free PBS. RNA extraction is performed with the "High Pure RNA Isolation Kit" (Roche Diagnostics) according to the manufacturer's instructions. Elution is performed in 100 μ l elution buffer.

Reverse transcription

10 10 μ l of the purified RNA were mixed with 1.25 μ g dT15 primer in a 20 μ l final volume. The RNA-primer mix was heated for 10 minutes at 70°C and then cooled to 4°C. The reverse transcription was realized using the following protocol:

In a 0.2ml tube were added:

15 -10 μ l of the above annealed primer-RNA mix
-5 μ l of 0.1M DTT
-2.5 μ l of dNTPs (10mM each)
-0.5 μ l RNase inhibitor (10u/ μ l, GibcoBRL)
-2.5 μ l M-MLV Reverse Transcriptase (200U/ μ l, GibcoBRL)
-10 μ l RT buffer (5x)
20 -H₂O to 50 μ l

This was incubated for 1 hour at 37°C, the enzyme was inactivated for 5 minutes at 95°C and cooled on ice. A tube containing the same components but no M-MLV Reverse Transcriptase was used as a negative control.

25

30 PCR on the cDNA

The primers used for the PCR amplification of the light and heavy chains cDNAs were designed according to Kang *et al.* (Kang, et al. 1991 Methods. A companion to Methods in Enzymology 2(2): 111-118):

Light chain	3' primer	L-Kappa3'	5' CGCCCGTCTAGAATTAAACACTCATTCCTGTTGAA 3'
	5' primers	Lvar 5'-1	5' CCAGTTCCGAGCTCGTTGTGACTCAGGAATCT 3'
		Lvar 5'-2	5' CCAGTTCCGAGCTCGTTGTGACCGCAGCCGCC 3'
		Lvar 5'-3	5' CCAGTTCCGAGCTCGTTGTGCTACCCAGTCCTCCA 3'
		Lvar 5'-4&7	5' CCAGTTCCGAGCTCG(G/C)(A/T)GATGAC(A/C)CAGTCCTCCA 3'
		Lvar 5'-5&6	5' CCAGATGTGAGCTCGT(G/C)ATGACCCAG(A/T)GG 3'
Heavy chain	5' primers	Hvar 5'-1-8	5' AGGTCCA(A/G)CT(G/T)CTCGAGTC(A/T)GG 3'
		Hvar 5'-9	5' AGGTIIAICTCTCGAGTC(A/T)GG 3'
	3' primers	HC _Y 3' 3'	5' GGGGGTACTAGTCTTGGGTATTCTAGGCTC 3'
		HC _μ 3'	5' ATTGGGACTAGTCTCTGCGACAGCTGGAAT 3'

PCR was accomplished as follows:

Mix in a 0.2ml reaction tube:

-5μl template (RT-PCR product or negative control)

5 -5μl reaction buffer (10x)

-1μl dNTPs (10mM each)

-1.5μl each primer (20μM stocks)

-2.5μl REDTaq polymerase (1U/μl, Sigma)

-H₂O to 50μl

10 The PCR reaction was performed with the following temperature cycling:

-4 min at 94°C

-35 times 30 seconds at 94°C

30 seconds at 52°C

1 min at 72°C

15 -4 min at 72°C

-4°C

These reactions were also performed on the negative controls from RT reactions (without M-MLV Reverse Transcriptase) to be sure that the PCR products are obtained from cDNA and not genomic DNA. No PCR products were obtained 20 from those negative controls. The obtained PCR products were purified with the "High Pure PCR Product Purification Kit" (Roche Diagnostics) according to the manufacturer's instructions.

Sequencing of the purified PCR products

25 To be sure that no sequence errors occurred because the sequencing was performed on a PCR product, sequencing was done on two independently-obtained PCR products for each cDNA to be sequenced.

Sequencing reactions were performed on 1 µl of the purified PCR products with the "ABI PRISM® BigDye™ Terminator Cycle Sequencing Kit" according to the manufacturer's instructions (Perkin-Elmer) and analyzed on a ABI PRISM 377 sequencer. Sequences of the light and heavy chains for the 4 monoclonal antibodies
5 are presented in SEQ ID NO:281-288.

Example 2: Isolation of *N. meningitidis* LOS peptidic mimotopes from phage-displayed peptidic libraries

Monoclonal antibodies directed against epitopes on bacterial polysaccharides,
10 as are the above-mentioned antibodies directed against *N. meningitidis* LOS, can be used to screen large repertoires of molecules. Such molecular libraries can chemically different, for example, peptides, peptoids, or nucleotides. Peptidic libraries can be obtained either synthetically (as soluble or support-bound peptides) or biologically (for example as fusions to a cytoplasmic or surface protein). One of the most often
15 used systems is the display of peptides fused to a coat protein of filamentous bacteriophages such as the pIII and pVIII proteins. These libraries are obtained by inserting an oligonucleotide containing a degenerate sequence in the 5' region of the ORF encoding one of these 2 proteins. The peptides expressed at the surface of the phage in fusion with the pIII or pVIII proteins are physically linked to their encoding
20 DNA since the filamentous phages consist of the phage circular single-stranded DNA surrounded by the structural proteins. Two phage-displayed peptidic libraries were used in this work for selection of peptides with five monoclonal antibodies. These two libraries are the nonamer linear and nonamer disulfide-constrained peptide libraries previously described (Felici et al. 1993 *Gene* 128: 21-27; Luzzago et al. 1993 *Gene*
25 128: 51-57). These libraries are constructed in a phagemid, the degenerate oligonucleotides being fused to the gene encoding the major capsid protein, pVIII. After transformation in *E. coli* and superinfection with phage helper, the resulting phage particles contain both recombinant and non-recombinant pVIII proteins, the proportion of recombinant pVIII proteins not being precisely defined. The five
30 monoclonal antibodies used for selection of peptides are the four described above, and the monoclonal antibody 4BE12C10 obtained from Ian Feavers (National Institute for Biological Standards and Control, London).

4BE12C10 was also used to select peptides from a mix of 4 other libraries. These libraries express peptides 14 to 16 amino acids in length fused to the pVIII

protein of the f88-4 filamentous phage. This vector, received from Georges Smith (Division of Biological Sciences, University Of Missouri-Columbia), has two gene VIIIIs: the wild-type gene and a synthetic recombinant gene under the control of the tac promoter, and is derived from the fd-tet phage (Smith, *Virology*, 167, 156-165, 1988). After infection of *E. coli*, the resulting phage particles contain both wild-type and recombinant pVIII proteins, the recombinant pVIII protein being a few to 10% of all pVIII proteins. The 4 libraries express peptides that contain two internal cysteines separated by 3, 4, 5 or 6 residues and are called Cys3, Cys4, Cys5 and Cys6, respectively.

10

2.1 Panning procedures

Three cycles of panning were performed. For mAbs H44/24 and H44/58, two procedures were used for immobilisation of phage-antibodies complexes: capture on

15 ProteinA-coated immunoplate (hereunder referred as procedure PA) or capture on ProteinA-coated magnetic beads (hereunder referred as procedure DY). For mAbs H44/70, H44/78 and 4BE12C10, phage-antibodies complexes were recovered by capture on ProteinLA-coated immunoplates.

20 2.1.1 ProteinA-coated immunoplates (PA) procedure (for H44/24 and H44/58)

During the first cycle, Maxisorp immunoplates (Nunc, Roskilde, Denmark) were coated overnight at 4°C with ProteinA (Sigma, St. Louis, USA) at 10 µg/ml of 0.1 M sodium carbonate (four wells with 100µl ProteinA solution for each mAb to be used). At the same time, a sample of the libraries mix ($5 \cdot 10^{10}$ pfu for each of the two libraries) was incubated overnight at 4°C with 10µg of mAb in the smallest possible volume (typically less than 40µl). The following day, after 1hr saturation (5mg/ml BSA, 0.1µg/ml ProteinA in 0.1M sodium carbonate) and 4 washes with Tris Buffered Saline (TBS, 50 mM Tris, 150 mM NaCl, pH 7.5) containing Tween20 0.5 % (v/v), the antibody-phages mixes were filled up to 400µl with the washing solution and four 30 100µl aliquotes were incubated for 3 hours at room temperature on the proteinA-coated dishes. After 10 washes with TBS-Tween20 0.5%, bound phages were eluted for 20 minutes at room temperature with a glycine buffer at pH 2.2. The eluate was immediately neutralized and used for amplification and titration of infectious phage

particles. The *E. coli* strain used for amplification and titration was DH11S (GibcoBRL). For the following cycles of biopanning, the same protocol was used but the amount of mAb was reduced to 1 μ g.

5 **2.1.2 ProteinA-coated magnetic beads (DY) procedure (for H44/24 and H44/58)**

For the first cycle, a sample of the libraries mix (5.10^{10} pfu for each of the two libraries) was incubated overnight at 4°C with 10 μ g of mAb in the smallest possible volume (typically less than 40 μ l). The following day, 40 μ l Dynabeads ProteinA (Dynal, Oslo, Norway) were washed 2 times with TBS-Tween, saturated for 1hr 10 (5mg/ml BSA, 0.1 μ g/ml ProteinA in 0,1M sodium carbonate) and washed 2 more times with TBS-Tween. The antibody-phage mixes were filled up to 40 μ l with the washing solution, mixed with the saturated Dynabeads ProteinA and incubated 3 hours at room temperature. After 10 washes with TBS-Tween20 0.5%, bound phages were eluted 20 minutes at room temperature with a glycine buffer at pH 2.2. The 15 eluate was treated as in Example 2.1.1. For the following cycles of biopanning, the same protocol was used but the amount of mAb was reduced to 1 μ g.

20 **2.1.3 ProteinLA-coated immunoplates procedure (for H44/70, H44/78 and 4BE12C10)**

The protocol used for this procedure is the same that for the ProteinA-coated immunoplate procedure except that ProteinA was replaced by ProteinLA (Clontech, Palo Alto, USA) and that non-purified concentrated hybridoma supernatant was used.

25 **2.1.4 Selection from the Cys3 to Cys6 library mix with monoclonal antibody 4BE12C10.**

The protocol was similar to the PA procedure discussed above in 2.1.1, except the following:

- 3.10^{10} TU of each library were used in the first panning
- monoclonal antibody 4BE12C10 was used in three different amounts for the three 30 panning cycles: 10 μ g for the first cycle, 1 μ g for the second cycle and 0.1 μ g for the third cycle.

- ProteinG (10 μ g/ml) was used to capture the phage-antibody complexes in the first and third panning rounds, and ProteinA (10 μ g/ml) was used to capture the phage-antibody complexes in the second panning round.

5 2.2 Amplification of phages

Phage eluates from the nonamer libraries were amplified by infection of *E. coli* (DH11S) and superinfection with helper phage M13KO7. A sample of the eluates (450 μ l out of the total 475 μ l of the first panning round or 100 μ l out of the total 475 μ l of the second or third panning rounds) was mixed with 1ml of terrific broth cells

10 (DH11S grown in terrific broth at OD600nm between 0.125 and 0.25 at dilution 10). Bacteria were kept 15 minutes at 37°C with slow agitation just before and after infection. Infected bacteria were then grown 30 minutes at 37°C with strong agitation and then spread on large LB plates supplemented with 100 μ g/ml ampicillin (LB Amp). The next day, the plates were scraped and a sample was added to 100ml LB
15 Amp to reach 0.05 OD600 nm. This culture was grown to a OD600nm between 0.2 and 0.25, the agitation was slowed down for 10 minutes and superinfection by helper phage was performed by adding M13KO7 at a MOI (multiplicity of infection) of 20. At this time, IPTG was added at a final concentration of 1mM. The culture was incubated 15 minutes at 37°C without agitation and grown 5 hours at 37°C with
20 strong agitation. Phages were recovered by precipitation of cleared supernatant with PEG-NaCl and titrated by infection of *E. coli* (DH11S) and spreading on LB Amp plates.

Phage eluates from the Cys3/4/5/6 libraries were amplified by infection of *E. coli* (K91kan). A sample of the eluates (450 μ l out of the total 475 μ l of the first panning round or 100 μ l out of the total 475 μ l of the second or third panning rounds) was mixed with 1ml of terrific broth cells (K91kan grown in terrific broth at OD600nm between 0.125 and 0.25 at one tenth dilution). Bacteria were kept 15 minutes at 37°C with slow agitation just before and after infection. Infected bacteria were then grown 30 minutes at 37°C with strong agitation in LB medium
25 supplemented with 0.2 μ g/ml tetracycline. Tetracycline was then added up to 20 μ g/ml and grow overnight at 37°C with strong agitation. Phages were recovered by precipitation of cleared supernatant with PEG-NaCl and titrated by infection of *E. coli* (K91kan) and spreading on LB Tet plates.

2.3 Screening by immunoblotting

2.3.1 Screening by colony immunoblotting

Screening by colony immunoblotting was done using *E. coli* (DH11S) infected with phage obtained after 3 panning cycles. Seven phage samples were used: one sample of phage selected with each of the monoclonal antibodies H44/70, H44/78 and 4 BE12C10, and two samples for each of the monoclonal antibodies H44/24 and H44/58. In the latter case, the two samples correspond to the two methods used for the pannings (referred as procedures PA and DY above).

Petri dishes containing ampicillin (100µg/ml) and 1 mM IPTG were used for spreading the phage-infected *E. coli* onto. Fresh colonies were blotted with nylon amphoteric membranes (Porablot NY amp, Macherey-Nagel, Düren, Germany) for 2 hours at 37°C. The membranes were subsequently saturated with 5% skimmed milk in TBS (2 hours at 37°C) and incubated with the corresponding monoclonal antibody. The binding of the monoclonal antibody to the recombinant pVIII proteins was revealed using GAM-HRP (Dako, Denmark) diluted 1000 times in saturation solution. The presence of the secondary antibody was in turn detected using HRP color development reagent (Bio-Rad, Hercules, USA).

2.3.2 Screening by culture supernatant immunoblotting

In the case of the screening of the two nonamer libraries with monoclonal antibody 4BE12C10, no positive clone could be revealed by the colony immunoblotting technique from either the second or third round of panning. In order to try to isolate some individual positive clones, a new experiment was set up which consisted of isolating 48 clones from each panning round and producing phages from these isolated clones in duplicate in a 96-well format allowing a quick isolation of positive clones in a culture supernatant immunoblot experiment. Culture and phage production by superinfection with M13KO7 helper phage were carried out as described in point 2.2 except that culture volumes were reduced to 500 µl to afford the 96-well format. Hundred microlitre of the culture supernatants were directly blotted on a nitrocellulose membrane in a 96-well format dot blotting device (BioRad) and treated as membranes of the colony immunoblotting experiment.

Monoclonal antibody binding was revealed by a chemiluminescent detection technique: membrane was incubated 10 minutes with LumiLight Plus substrate (Roche Diagnostics) at room temp. in the dark, and light emission was detected by

putting the membrane in contact with an autoradiography film for 30 seconds to a few minutes in an autoradiography cassette. A similar blot was incubated with an anti-phage serum to check for the presence of phage particles in similar amounts in all phage-containing wells.

5

2.4 Sequence determination of selected peptides

The sequence of the selected peptides was determined using a two-step procedure. In the first step, the recombinant gene 8 was amplified by polymerase chain reaction (PCR) using oligonucleotides annealing upstream (5'-

10 ATTCTAGAGATTACGCC-3' for the nonamer libraries or 5'-
CCCATCCCCCTGTTGACAAT-3' for the Cys3/4/5/6 libraries) and downstream (5'-
TGCTGCAAGGCGATTAAGTT-3' for the nonamer libraries or 5'-
ATTAGGCAGGCTGGGTATCT-3' for the Cys3/4/5/6 libraries) of the region coding
15 for the presented peptide. The PCR were carried out with the *Tth* thermostable DNA
polymerase (BIOTOOLS, Madrid, Spain) in duplicate in order to check for possible
risks or errors during amplification. The PCR products were sequenced using with
the M13-40 Forward primer (5'-GTTTCCCCAGTCACGAC-3') (for peptides derived
15 from the nonamer libraries) or with 5'-CATCGGCTCGTATAATGT-3' (for peptides
derived from the Cys3/4/5/6 libraries) using the "ABI PRISM® BigDye™ Terminator
20 Cycle Sequencing Kit" according to the manufacturer's instructions (Perkin-Elmer)
and analyzed on a ABI PRISM 377 sequencer.

148 different sequences were obtained distributed as follows:

- 1 peptide selected with monoclonal antibodies H44/24, H44/58, H44/70 and
25 H44/78 (sequence N° 1)
- 11 peptides selected only with monoclonal antibody H44/24 (either by procedure
DY or procedure PA) (sequences N° 2 to 12)
- 30 peptides selected only with monoclonal antibody H44/58 (either by procedure
DY or procedure PA) (sequences N° 13 to 43, except 17)
- 1 peptide selected with monoclonal antibody H44/58 (either by procedure DY or
procedure PA) and monoclonal antibody H44/70 (sequence N° 17)
- 3 peptides selected with monoclonal antibodies H44/70 and H44/78 (sequences N°
44 to 46)

- 28 peptides selected only with monoclonal antibody H44/70 (sequences N° 47 to 74)
- 21 peptides selected only with monoclonal antibody H44/78 (sequences N° 75 to 95)
- 5 • 53 peptides selected only with monoclonal antibody 4 BE12C10 (sequences N° 96 to 148). Sequences 141 and 142 are from phage derived from the cysteine-bridged nonamer library. Sequences 143 to 145 are from phage derived from the linear nonamer library. Sequences 146 to 148 are from phage derived from the Cys6, Cys5 and Cys3 libraries, respectively.

10 These sequences are presented in Table 2 below.

Table 2. Sequences of the 148 selected phage-displayed peptides.

No.	Sequence	SEQ ID	No.	Sequence	SEQ ID	No.	Sequence	SEQ ID
1	CNTKWYPYAC	141	48	ESPYSAHRW	48	95	WYVGSVRSQ	95
2	CFVPSPVYVEC	142	49	WYDERTILK	49	96	CALDIAGGYIC	236
3	CRSSLPGDC	143	50	CSSYSVYHDSC	190	97	CPPPSRGYGYC	237
4	FYRELAGDL	4	51	CRFTYDPPFMC	191	98	CQAQFTDVTWTC	238
5	MRRTASEIM	5	52	CFYLSFVFDKC	192	99	FLPCRRCGS	99
6	MRPLTWQTT	6	53	SQWRSAAPT	53	100	RPWQTAHFA	100
7	MRRIIPEGT	7	54	CRPAFDPPYHC	194	101	GQYSSSPFP	101
8	MRDVMPOWH	8	55	HGRTLWYTP	55	102	CGRPGPYPADC	242
9	HKPTDHPSW	9	56	CSSVSATYPIC	196	103	CTPLPDGGILC	243
10	CSETYGRPGLC	150	57	CSLVSQPKRKC	197	104	LKWGDGSSA	104
11	ERPIGGDSG	11	58	SNWYENTPT	58	105	CYPQLSHANPC	245
12	RMRDIPGAP	12	59	PRPQGWQSA	59	106	CSAYHRSLLGAC	246
13	CISEYAKGTC	153	60	CTDPRGCGGMFA	60	107	CFPLPSRFAF	247
14	CSHAPPYDRC	154	61	PRPHFGAPP	61	108	YRQSRSSWP	108
15	CVTIPYRGTCC	155	62	CVTRATYPSWC	202	109	SHRFDALRK	109
16	CFAPPYDPLPC	156	63	WYIAPRKTL	63	110	CVRFPDGSHSC	250
17	CAPYSIFIGEC	157	64	CYCGYSALRDT	204	111	CSPAFAFSDRLC	251
18	CTLGHYHGTC	158	65	CIITGSHWYVC	205	112	CVTDQWGGYGLC	252
19	CLCQAYKGRRC	159	66	CTHYSFGYDIC	206	113	CPVPSGRSPNTC	253
20	CDPRLLDLC	160	67	HWYSTEAW	67	114	PKWSDKRPQ	114
21	KTALPPYDR	21	68	HRIAQSLPQ	68	115	CAPPGIAVRTC	255
22	CAFARPFGTWC	162	69	CALYRFAADSC	209	116	MKWGPNSHS	116
23	CSSLSPYDRC	163	70	CRQCPDPPNDC	210	117	CLQDRAGGYGLC	257
24	CDRTSLALAC	164	71	CHPALARWPLC	211	118	CGLEGRGCRSHA	118
25	CRAPPYDTIMC	165	72	QPKSLWVSY	72	119	CYFAKHGVAC	259
26	CPPYDEGCRVA	26	73	CRGYSVHSAC	213	120	CPPRSSRGFLC	260
27	CGFLIAFHPC	167	74	COPVRTYPIC	214	121	CTGISTGELYC	261
28	CQPIGPPYDRC	168	75	WYTTPTTRPV	75	122	GPVYATGL	122
29	CTANYFGFTYC	169	76	QRQSLWYSS	76	123	CLSQYADWTYC	263
30	CANSRPGGGLC	170	77	NPDYSSPHE	77	124	ARWYPIQSQT	124
31	CMSYYGRGVKT	171	78	PPWYPEHKT	78	125	CQGFPGAPQDC	265
32	CVSTPFRGTF	172	79	CSASLGLAKTTC	219	126	WHFRFTFPAT	126
33	CDPRITPDFFC	173	80	WYVDGPLAT	80	127	TRRPFDPAA	127
34	CGPPYDPFFAC	174	81	RGWYADPSA	81	128	CASPLGPCFW	128
35	CHTVFRFGTLC	175	82	CLWRPVIDPFLC	222	129	CWTDTYGDLLC	269
36	CTAPPYDAYGC	176	83	AERSPYWYYP	83	130	CISAGPESSHC	270
37	CRSPLLGAPVC	177	84	PPWYNNQSEL	84	131	CHSVQPATRAC	271
38	CTTYYGTGTC	178	85	QSAPAVKSS	85	132	CPKAPFSPFKC	272
39	CSSLYYHGTC	179	86	PGWYDAHPT	86	133	CIDAGSHGWLC	273
40	CLYEPLRGLTC	180	87	CRGLQGHHIAYC	227	134	CRRGSPSLSRYC	274
41	CAPPYDQSFAC	181	88	WYSAPENAL	88	135	SWDEIIDLG	135
42	CPPPWYSRSSC	182	89	WYTAPSSL	89	136	CRSPAGEWSSC	276
43	CSRALGYVSEC	183	90	WYTNPSIAA	90	137	CAYHVLRYSC	277
44	PTWYKLVSKV	44	91	WYFSNENLQ	91	138	CAKTVRGDYYC	278
45	RGSEGSFAR	45	92	WYTLIDGPT	92	139	CLAASADTAAC	279
46	CKOTIGSFDC	186	93	GPWHGPSS	93	140	CPYTSWAREGC	280
47	PLWYDPAPP	47	94	GDWPWFPSAP	94	141	CPPPWSTHDC	297

No.	Sequence	SEQ ID
142	CSEPWSTNSC	298
143	AITGVRARW	291
144	EKKHFNYGT	292
145	EKKRFESNT	293
146	EQGYCTVNIEQCAKYR	294
147	SPADCDYTTLCAKPT	295
148	NSPTSCWKLNEKF	296

Example 3 ELISA tests for the peptide-on-phage mAb interaction.

To assess the binding of the mAbs to the numerous peptides-on-phage, all clones have been produced independently using the following protocol.

5 *For clones from the nonamer libraries (Table 2, Peptide Nos 1 to 145).*

A preculture of *E. coli* DH11S infected with the phage was grown overnight. A sample of this preculture was used to inoculate a new 50 ml culture with a starting OD_{600nm} of 0.050. This culture was grown up to an OD_{600nm} of 0.20 to 0.25 with vigorous shaking at 37°C. The culture was then slowed down for 15 minutes in order 10 to allow the regeneration of pili. M13K07 helper phage was added at an MOI of 20, and superinfection was allowed for 15 more minutes at 37°C with slow agitation. IPTG (1mM final concentration) was then added and the culture was grown for 5 hours with vigorous agitation.

15 *For clones from the Cys3/4/5/6 libraries (Table 2, peptide Nos. 146 to 148).*

A colony of K91kan containing the clone of interest (on a LB Tet plate) was added to 50ml of LB supplemented with 20µg/ml tetracycline and grown overnight at 37°C with strong agitation.

20 *For all clones.*

Culture was centrifuged for 15 minutes at 4000RPM; 0.15 volume of PEG- NaCl solution was added to the supernatant for precipitating the phage and kept 25 overnight at 4°C. Phage were collected by centrifugation, 45 minutes at 4000RPM. After being resuspended in TBS, phage were heated 15 minutes at 65°C to kill remaining bacteria and to denature soluble proteins present in the sample. The solution was then centrifuged and the pellet was discarded. Phage in the supernatant were then precipitated again as indicated above. Phage were finally resuspended in 200µl of TBS. Concentration of phage particules was determined by measuring the ΔOD at 269nm-320nm.

The ELISA test

30 Phages were coated at 5x10¹¹particules/ml on MaxiSorp multiwell plates. Coating was performed overnight at 4°C with 100µl/well. Plates were saturated with 5% (w/v) skimmed milk in TBS for 2 hours at 37°C and washed 5 times with TBS-Tween₂₀ 0.05 % (v/v). The mAbs were then incubated in the coated wells for 1 hour at 37°C, washed 5 times, and GAM-HRP conjugate (1500-fold dilution, Dako,

Denmark) was added for 1 hour at 37°C to detect the binding of the mAb to the phages. After 5 washings, the peroxidase activity was monitored by addition of the K-Blue® substrate (Neogen, Lexington, USA) at room temperature for 20 minutes. Reaction was stopped by addition of 25µl of 2N H₂SO₄. Reading was performed at 5 450-630nm. Each phage was coated in triplicate for testing with each mAb. Control mAbs are of the same isotype as the selecting mAbs but do not react with *N. meningitidis* B.

Results

10 All phages that were positive with one or more than one mAb were tested a second time to confirm the result. Forty-six peptides were shown to be positive with at least one mAb. These are peptide number (with reference to Table 2): 13, 14, 17, 22, 27, 28, 29, 30, 39, 45, 47, 50, 51, 53, 54, 55, 58, 61, 63, 66, 75, 82, 83, 85, 86, 87, 88, 93, 103, 104, 105, 115, 124, 131, 132, 133, 139, 140, 141, 142, 143, 144, 145, 146, 15 147, 148. This supports the view that they are particularly suitable as mimotopes of the meningococcal L3,7,9 LOS.

Hundred and two out of the 148 selected peptides were not detected as positive in this test. For at least some of these, this could be due to bad expression of the peptide at the surface of the phage, especially for those peptides which share a 20 conserved motif with other peptides that are positive in the test. In such case, a more sensitive test may show that some of these peptides are indeed recognized by one or more mAbs.

Example 4 SPOT Peptides

25 Another experiment for determining the best peptide candidates for immunisation trials is whether chemically synthesized peptides are recognized by at least one anti-MenB LOS mAb (and preferably not by irrelevant mAbs). This can be assessed on SPOT synthesized peptides (peptides synthesized directly on a cellulose membrane). This membrane can be tested with different mAbs by repetitive 30 immunoblotting and chemiluminescent detection. Peptides may be synthesised with 3 residues originating from the pVIII protein sequence on each end of the peptide. Indeed, the primary structure of the peptides expressed in fusion with pVIII on the surface of the bacteriophage is as follows (x for any residue in the library):

- linear peptides (9aa): AAEGEFxxxxxxxxxDPKAQAF....

- cyclic peptides (C9aaC): AAEGEFCxxxxxxxxxCGDPAKAAF...

Linear and cyclic peptides may be synthesised on distinct membranes to enable specific regeneration of cyclic peptides.

For example linear peptides comprising peptide No. 61 from Table 2 (GEFPRPHFGAPPDPA) and peptide No. 83 (GEFAERSLWYYPDPA) were synthesised on one membrane, and cyclised peptides comprising peptide No. 50 from Table 2 (GEFCSSYSYVHDSCGDP), peptide 14 (GEFCSHAPPYDRVCGDP) and peptide 25 (GEFCRAPPYDTIMCGDP) were synthesised on another.

The protocol used to probe these membranes with mAbs was the one provided by Genosys, with some modifications, especially for the regeneration of membranes with cyclised peptides. Briefly, membranes were washed 3 x 10 minutes (washing buffer is TTBS: TBS pH8, Tween 20, 0,05%) saturated for 1 hour at room temp. in blocking buffer (Blocking buffer concentrate Genosys SU-07-250, 10 times diluted in TTBS, 0,05g/ml sucrose), washed again for 1 minute in TTBS, incubated for 2 hours (rocking gently) at room temp. with mAb diluted in blocking buffer, washed 2 x 1 minute and 3x 10 minutes with TTBS, incubated 1h30 (rocking gently) at room temp. with secondary antibody (Goat anti-mouse-HRP, Dako) diluted 1500x in blocking buffer, washed 2 x 1 minute and 3x 10 minutes with TTBS, and measured by chemiluminescent detection (incubated 10 minutes with LumiLight Plus (Roche Diagnostics) at room temp. in the dark and light emission was detected on a Fluor-S MultiImager System (BioRad) for 3 to 30 seconds or by autoradiography on X-ray film).

Results are reported in the tables below. First column is the number of the peptide. MAbs (in bold), are indicated in the order they were used in the successive experiments.

Mabs used: MAb 24 (H44/24), 58 (H44/58), 47 (4BE12C10) and 2C8 (an irrelevant mAb) are IgG3; MAbs 70 (H44/70), 78 (H44/78), M4 (directed against streptococcal polysaccharide), M13 (id.) and F76 (generated against a peptide epitope) are IgMs. G stands for GAM-HRP alone (no primary mAb).

30

Membrane 1 (linear peptide)

Membrane 1 (linear peptide)										
	70	Gam	78	47	M4	58	M13	24	G	F75
83	+++		+	(+)	++	(+)	++	++		++
61	+			+						+/-

Membrane 2 (cyclic peptides)

	58	G	24	70	78	M13	47	70	2C8	F76
14	++			+		+				(+)
25	(+)					(+)				(+)
50				++	+	+		++		(+)

After detection, blots were regenerated as follows: washed 3 x 10 minutes in

5 TTBS; washed 2 x 1 minute and 3 x 10 minutes in regeneration buffer at 50°C (regeneration buffer is: 50mM Tris-HCl, pH 6.7; 2% SDS; 2-mercaptoethanol 100mM); washed 3 x 10 minutes in PBS (only for cyclic peptides); washed 2 x 1 minutes and then overnight in PBS-DMSO 10% (only for cyclic peptides); and washed 3 x 10 minutes in TTBS.

10 From the experiment it can be concluded that Peptide 61 is specifically recognized by mAb H44/70 and Peptide 50 is recognized by mAb H44/70, H44/78 and M13 but the signal level is higher with mAb H44/70 than with other mAbs. Peptide 83 is recognized by all IgMs but the signal is higher with mAb H44/70 than with other mAbs. This peptide is also recognized by mAbs H44/24 and H44/58 and

15 not by other IgG3. Peptides 14 and 25, positive only with mAb H44/58 in phage-ELISA, were positive in SPOT synthesis with the same mAb and no other IgG3.

Example 5 Analysis of the Peptide Structure

The peptides isolated in this study appear to be quite dissimilar to the set of

20 L3,7,9 LOS peptide mimotopes disclosed in WO 00/25814.

148 peptides were found in this study (see Table 2). Many of them have, by design, one Cys residue at both ends, to make them cyclic via a disulphide bridge. In order to avoid, in the alignment and pattern search procedures, any bias due to these Cys, the peptides have been trimmed of their terminal cysteines; the original presence

25 of cysteines in the peptides can be recognized in the last two characters of their names (CC stands for one Cys at both ends, CN stands for one cys at N-ter, and no cys at C-ter, NC is the reverse, and NN when no terminal cys at any end).

The average amino acid composition of the peptides has two striking features : they seem to be enriched in Prolines (98/148 have at least one Proline) and even more

30 so in aromatic residues (Tyr, Trp and Phe) (126 peptides have at least one aromatic residue).

37

In particular, seven peptides (4, 2, 18, 50, 64, 83, 123) have the motif [YW]_nY, reported to be able to mimic carbohydrate subunits (C.D.Partidos, Current Opinion in Mol.Therapeutics, Vol 2, pp74-79, 2000).

One might think that the presence of a disulfide bridge would favour prolines in the peptides, but the unconstrained peptides contain prolines almost as frequently.

Conserved patterns were searched for, with the following results.

Strong similarities shared by some peptides

Some peptides share a number of consecutive residues, as shown in the following table:

Number of peptides	Motif shared	Peptide numbers
2	L-P-P-Y-D-R	21,23
4	P-P-Y-Y-D-R	14,21,23,28
4	A-P-P-Y-D	14,16,25,36
2	P-P-Y-D-P	16,34
2	G-P-P-Y-D	28,34
2	A-G-G-Y-L	96,117
2	S-L-W-Y-S	72,76
2	S-R-S-S	42,108
3	P-P-W-Y	42,78,84
10	P-P-Y-D	See below
2	R-G-T-L	35,40
3	F-D-P-P	54,70,127
2	A-T-Y-P	56,62
2	P-G-A-P	12,125
2	G-R-P-G	10,102
2	F-R-G-T	32,35
4	G-G-Y-L	30,96,112,117
2	S-L-S-L	23,89
3	S-L-W-Y	72,76,83

One should particularly notice the large number (10) of peptides sharing the PPYD motif.

15

```

LTpep_14_CC : shaPPYDrv
LTpep_16_CC : faPPYDplp
LTpep_21_NN : ktalPPYDr
LTpep_23_CC : sislPPYDr
LTpep_25_CC : raPPYDtim
LTpep_26_CN : PPYDegrvc
LTpep_28_DR : qpigPPYDr
LTpep_34_CC : gPPYDpfpa
LTpep_36_CC : taPPYDayg
LTpep_41_CC : apPPYDosf

```

There are 17 peptides having the motif PP[YFW].

The doublet WY is especially frequent in the set, with a count of 26 peptides.

The next most frequent dipeptide is PP (24) followed by AP (20).

5 Weaker similarities shared by many peptides

If intervening mismatches are accepted, the following sets of related peptides are found:

10 LT pep_54_CC : RP aFDPPyh
LT pep_70_CC : RP qFDPPnd

LT pep_96_CC : alDiAGGYL
LT pep_117_CC : lqDrAGGYL

15 LT pep_89_NN : WYT aPSlsl
LT pep_90_NN : WYT nPSiaa

LT pep_78_NN : PpWYpeHkT
LT pep_86_NN : PgWYdaRpT

20 LT pep_7_NN : RMRiIPegT
LT pep_12_NN : RMRdIPgap

25 LT pep_16_CC : faPPYDp1P
LT pep_34_CC : gPPYDpfpA

LT pep_52_CC : R1YSfVfDk
LT pep_73_CC : RgYShVsDa

30 LT pep_47_NN : P1WYdpapp
LT pep_86_NN : PgWYdahPt
LT pep_78_NN : PpWYpehkt
LT pep_86_NN : PgWYdahtp
LT pep_42_CC : pPpWYsrss
35 LT pep_84_NN : PpWYnqsel

LT pep_75_NN : WYTtPtrpv
LT pep_89_NN : WYT aPs1sl
LT pep_90_NN : WYTnPSiaa

40 LT pep_63_NN : WY1APrktL
LT pep_88_NN : WYsAPenal
LT pep_89_NN : WYtAPs1sL

45 Allowing for weaker patterns, we can group the last two sets with the pattern WYxxP, and add another peptide:

LT pep_81_NN : rgWYadPsa
LT pep_63_NN : WYiaPrkal
50 LT pep_88_NN : WYsaPenal

LTpep_75_NN : WYttPtrpv
LTpep_89_NN : WYtaPs1sl
LTpep_90_NN : WYtnPs1aa

5 If some more flexibility is introduced by allowing for gaps in the alignments, even more peptides may be grouped; for example:

10 LTpep_54_CC : RPaFDPPyh
LTpep_70_CC : RPqFDPPnd
LTpep_127_NN: trRP-FDPPa

15 LTpep_21_NN : ktAl-PPYDz
LTpep_41_CC : Ap-PPYDgsf
LTpep_54_CC : rpafdPPYH

20 LTpep_47_NN : p1WYd-Papp
LTpep_55_NN : hgrtlWYt-P
LTpep_63_NN : WYiaPrktl
LTpep_75_NN : WYttPtrpv
LTpep_81_NN : rgWYadPsa
LTpep_83_NN : aerslWYy-P
LTpep_88_NN : WYsaPenal
LTpep_89_NN : WYtaPs1sl
LTpep_90_NN : WYtnPs1aa

25 Other consensus sequences:

Peptide 141 cppPWSThdC
Peptide 142 csePWSTSnc
Consensus FWST

30 Peptide 144 EKKhFnygT
Peptide 145 EKKrFesnT
Consensus EKKxFxxxT

35 A Comparison of the Selected Peptides selected in Example 3

Two thirds of the peptides are constrained by a disulphide bridge, which means that this feature is not necessarily essential.

	SEQ ID NO:1	NTKWYPYA
	SEQ ID NO:2	FVPSPYVYE
	SEQ ID NO:3	RSSLPGD
5	SEQ ID NO:4	FYRELAGDL
	SEQ ID NO:5	MRRTASEIM
	SEQ ID NO:6	MRPLTWQTT
	SEQ ID NO:7	RMRIIPEGT
	SEQ ID NO:8	MRDVMPQHW
10	SEQ ID NO:9	HKPTDHPSW
	SEQ ID NO:10	SETYGRPGL
	SEQ ID NO:11	ERPIGGDSG
	SEQ ID NO:12	RMRDIPGAP
	SEQ ID NO:13	ISEYAKGTT
15	SEQ ID NO:14	SHAPPYDRV
	SEQ ID NO:15	VTIPYRGTO
	SEQ ID NO:16	FAPPYDPLP
	SEQ ID NO:17	APYSIFIGE
	SEQ ID NO:18	THLYHYGTS
20	SEQ ID NO:19	LCQAYKGRR
	SEQ ID NO:20	DPRLLDL
	SEQ ID NO:21	KTALPPYDR
	SEQ ID NO:22	FARPFQGTW
	SEQ ID NO:23	SLSLPPYDR
25	SEQ ID NO:24	DRTLSALAL
	SEQ ID NO:25	RAPPYDTIM
	SEQ ID NO:26	CPPYDEGCRVA
	SEQ ID NO:27	FGLIAFHPD
	SEQ ID NO:28	QPIGPPYDR
30	SEQ ID NO:29	TANYYFGTY
	SEQ ID NO:30	ANSRPGGYL
	SEQ ID NO:31	MSSYGRGVR
	SEQ ID NO:32	VSTPFRGTF
	SEQ ID NO:33	DPRITPDFG
35	SEQ ID NO:34	GPPYDPFP
	SEQ ID NO:35	HTVRFRGTL
	SEQ ID NO:36	TAPPYDAYG
	SEQ ID NO:37	RSPLLGAPV
	SEQ ID NO:38	TTTYGTGTW
40	SEQ ID NO:39	SSLYYHGT
	SEQ ID NO:40	LYEPLRGTL
	SEQ ID NO:41	APPPYDQSF
	SEQ ID NO:42	PPPWYSRSS
	SEQ ID NO:43	SRALGYVSE
45	SEQ ID NO:44	PTWYKLKSV
	SEQ ID NO:45	RGSEGSFÄR
	SEQ ID NO:46	KQTIGSFDG
	SEQ ID NO:47	PLWYDAPP
	SEQ ID NO:48	ESPYSAHRW
50	SEQ ID NO:49	WYDERTILK

SEQ ID NO:50	SSYSYVHDS
SEQ ID NO:51	RFTYDPPFM
SEQ ID NO:52	RLYSFVFDK
SEQ ID NO:53	SQWRSAAPT
5 SEQ ID NO:54	RPAFDPPYH
SEQ ID NO:55	HGRTLWYTP
SEQ ID NO:56	SSVSATYPI
SEQ ID NO:57	SLVQSPKRF
SEQ ID NO:58	SNWYENTPT
10 SEQ ID NO:59	PRPGWGQSA
SEQ ID NO:60	CTDPRGCGMFA
SEQ ID NO:61	PRPHFGAPP
SEQ ID NO:62	VTRATYPSW
SEQ ID NO:63	WYIAPRKT
15 SEQ ID NO:64	YGYSLRDT
SEQ ID NO:65	IITGSGWYV
SEQ ID NO:66	THYSFYGDI
SEQ ID NO:67	HWYSTEAAW
SEQ ID NO:68	HRIAQSLPQ
20 SEQ ID NO:69	ALYRFAADS
SEQ ID NO:70	RPQFDPPND
SEQ ID NO:71	HPALARWPL
SEQ ID NO:72	QPKSLWYSV
SEQ ID NO:73	RGYSHVSDA
25 SEQ ID NO:74	DPVRTIYPI
SEQ ID NO:75	WYTTPTRPV
SEQ ID NO:76	QRQSLWYSS
SEQ ID NO:77	NPDYSSPHE
SEQ ID NO:78	PPWYPEHKT
30 SEQ ID NO:79	ASLGLAKTT
SEQ ID NO:80	WYVDGPLAT
SEQ ID NO:81	RGWYADPSA
SEQ ID NO:82	LWRPIDPFL
SEQ ID NO:83	AERSLWYYP
35 SEQ ID NO:84	PPWYNQSEL
SEQ ID NO:85	DSAPAVKSS
SEQ ID NO:86	PGWYDAHPT
SEQ ID NO:87	RGLQGHIAY
SEQ ID NO:88	WYSAPENAL
40 SEQ ID NO:89	WYTAPSLS
SEQ ID NO:90	WYTNPSIAA
SEQ ID NO:91	WYFSNEnLG
SEQ ID NO:92	WYTLDIGPT
SEQ ID NO:93	GPWHGPSSS
45 SEQ ID NO:94	GDWPPFSAP
SEQ ID NO:95	WYVGSVRSQ
SEQ ID NO:96	ALDIAGGYI
SEQ ID NO:97	PPPSRGGYI
SEQ ID NO:98	QAFDTSWTA
50 SEQ ID NO:99	FLPCRRCGS

SEQ ID NO:100	RPWQTAHF A
SEQ ID NO:101	GQYSSSPFP
SEQ ID NO:102	GRPGPYPAD
SEQ ID NO:103	TPLPDGGIL
5 SEQ ID NO:104	LKWGDGSSA
SEQ ID NO:105	YPQLSHANP
SEQ ID NO:106	SAYHRSLGA
SEQ ID NO:107	FPLPSREFA
SEQ ID NO:108	YRQSRSSWP
10 SEQ ID NO:109	SHRFDALRR
SEQ ID NO:110	VRFPDGSHS
SEQ ID NO:111	SPAAFSDRL
SEQ ID NO:112	VTDQWGGYL
SEQ ID NO:113	VPSGRSPNT
15 SEQ ID NO:114	PKWSDKRPQ
SEQ ID NO:115	APPGIAVRT
SEQ ID NO:116	MKWGPNSHS
SEQ ID NO:117	LQDRAGGYL
SEQ ID NO:118	CGRLEGRCSHA
20 SEQ ID NO:119	YFIAKHGWA
SEQ ID NO:120	PPRSSRGFL
SEQ ID NO:121	TGISTGEYL
SEQ ID NO:122	GPVFYATGL
SEQ ID NO:123	LSQYADWTY
25 SEQ ID NO:124	ARWYPISQT
SEQ ID NO:125	QGFPGAPQD
SEQ ID NO:126	WHFRTPFPAT
SEQ ID NO:127	TRRFDPDPA
SEQ ID NO:128	CASPLGPCFW
30 SEQ ID NO:129	WTDTYGDLL
SEQ ID NO:130	ISAGPESSH
SEQ ID NO:131	HSVQPATRA
SEQ ID NO:132	PKAFTPSPFK
SEQ ID NO:133	IDAGSHGWL
35 SEQ ID NO:134	RRGSPLSRY
SEQ ID NO:135	SWDEIIDLG
SEQ ID NO:136	RSPAGEWSS
SEQ ID NO:137	AYHVLRYSA
SEQ ID NO:138	AKTVRGDY Y
40 SEQ ID NO:139	LAASADTAA
SEQ ID NO:140	PYTSWAREG
SEQ ID NO:141	CNTKWYPYAC
SEQ ID NO:142	CFVPSPYVYEC
SEQ ID NO:143	CRSSLPGDC
45 SEQ ID NO:144	CFYRELAGDLC
SEQ ID NO:145	CMRRRTASEIMC
SEQ ID NO:146	CMRPLTWQTTC
SEQ ID NO:147	CRMRIIPEGTC
SEQ ID NO:148	CMRDVMPQHWC
50 SEQ ID NO:149	CHKPTDHPSWC

	SEQ ID NO:150	CSETYGRPGLC
	SEQ ID NO:151	CERPIGGDSGC
	SEQ ID NO:152	CRMRDIPGAPC
	SEQ ID NO:153	CISEYAKGTTTC
5	SEQ ID NO:154	CSHAPPYDRVC
	SEQ ID NO:155	CVTIPYRGTQC
	SEQ ID NO:156	CFAPPYDPLPC
	SEQ ID NO:157	CAPYSIFIGEC
	SEQ ID NO:158	CTHLYHYGTSC
10	SEQ ID NO:159	CLCQAYKGRRCC
	SEQ ID NO:160	CDPRLLDLC
	SEQ ID NO:161	CKTALPPYDRC
	SEQ ID NO:162	CFARPFQGTWC
	SEQ ID NO:163	CSLSLPPYDRC
15	SEQ ID NO:164	CDRTLSALALC
	SEQ ID NO:165	CRAPPYDTIMC
	SEQ ID NO:166	CPPYDEGCRVAC
	SEQ ID NO:167	CFGGLIAFHPC
	SEQ ID NO:168	CQPIGPPYDRC
20	SEQ ID NO:169	CTANYYFGTYC
	SEQ ID NO:170	CANSRPGGYLCC
	SEQ ID NO:171	CMSSYGRGVRC
	SEQ ID NO:172	CVSTPFRGTPC
	SEQ ID NO:173	CDPRITPDFGC
25	SEQ ID NO:174	CGPPYDPFFAC
	SEQ ID NO:175	CHTVRFRGTLCC
	SEQ ID NO:176	CTAPPYDAYGC
	SEQ ID NO:177	CRSPLLGAPVC
	SEQ ID NO:178	CTTYGTGTWC
30	SEQ ID NO:179	CSSLYYHGTAC
	SEQ ID NO:180	CLYEPLRGTLCC
	SEQ ID NO:181	CAPPYDQSFC
	SEQ ID NO:182	CPPPWYSRSSC
	SEQ ID NO:183	CSRALGYVSEC
35	SEQ ID NO:184	CPTWYKLKSVC
	SEQ ID NO:185	CRGSEGSFARC
	SEQ ID NO:186	CKQTIGSFDFGC
	SEQ ID NO:187	CPLWYDPAPPC
	SEQ ID NO:188	CESPYSAHRWC
40	SEQ ID NO:189	CWYDERTILKC
	SEQ ID NO:190	CSSYSYVHDSC
	SEQ ID NO:191	CRFTYDPPFMC
	SEQ ID NO:192	CRLYSFVFDKC
	SEQ ID NO:193	CSQWRRSAAPTC
45	SEQ ID NO:194	CRPAFDPPYHC
	SEQ ID NO:195	CHGRRTLWYTPC
	SEQ ID NO:196	CSSVSATYPIC
	SEQ ID NO:197	CSLVQSPKRFC
	SEQ ID NO:198	CSNWyENTPTC
50	SEQ ID NO:199	CPRPGWGQSAC

	SEQ ID NO:200	CTDPRGCGMFAC
	SEQ ID NO:201	CPRPHFGAPPC
	SEQ ID NO:202	CVTRATYPSWC
	SEQ ID NO:203	CWYIAPRKTL
5	SEQ ID NO:204	CYGYALSARDTC
	SEQ ID NO:205	CIIITGSGWYVC
	SEQ ID NO:206	CTHYSFYGDIC
	SEQ ID NO:207	CHWYSTEAAWC
	SEQ ID NO:208	CHRIAQSLPQC
10	SEQ ID NO:209	CALYRFAADSC
	SEQ ID NO:210	CRPQFDPPNDC
	SEQ ID NO:211	CHPALARWPLC
	SEQ ID NO:212	CQPKSLWYSVC
	SEQ ID NO:213	CRGYSHVSDAC
15	SEQ ID NO:214	CDPVRTIYPIC
	SEQ ID NO:215	CWYTTTPTRPVC
	SEQ ID NO:216	CQRQSLWYSSC
	SEQ ID NO:217	CNPDYSSPHEC
	SEQ ID NO:218	CPPWYPEHKTC
20	SEQ ID NO:219	CASGLAKTTC
	SEQ ID NO:220	CWYVDGPLATC
	SEQ ID NO:221	CRGWWYADPSAC
	SEQ ID NO:222	CLWRPIDPFLC
	SEQ ID NO:223	CAERSLWYYPC
25	SEQ ID NO:224	CPPWYNQSEL
	SEQ ID NO:225	CDSAPAVKSSC
	SEQ ID NO:226	CPGWYDAHPTC
	SEQ ID NO:227	CRGLQGHIAYC
	SEQ ID NO:228	CWYSAPENALC
30	SEQ ID NO:229	CWYTAPSLSLC
	SEQ ID NO:230	CWYTNPSSAAC
	SEQ ID NO:231	CWYFSNEeLGC
	SEQ ID NO:232	CWYTLDIGPTC
	SEQ ID NO:233	CGPWHGPSSSC
35	SEQ ID NO:234	CGDWPPFSAPC
	SEQ ID NO:235	CWYVGSVRSQC
	SEQ ID NO:236	CALDIAGGYIC
	SEQ ID NO:237	CPPPSRGGYIC
	SEQ ID NO:238	CQAFDTSWTAC
40	SEQ ID NO:239	CFLPCRRCGSC
	SEQ ID NO:240	CRPWQTAHFAC
	SEQ ID NO:241	CGQYSSSPFPC
	SEQ ID NO:242	CGRPYPAD
	SEQ ID NO:243	CTPLPDGGILC
45	SEQ ID NO:244	CLKWGDGSSAC
	SEQ ID NO:245	CYPQLSHANPC
	SEQ ID NO:246	CSAYHRSLGAC
	SEQ ID NO:247	CFPLPSREFAC
	SEQ ID NO:248	CYRQSRSSWPC
50	SEQ ID NO:249	CSHRFDALRRC

SEQ ID NO:250	CVRFPDGSHSC
SEQ ID NO:251	CSPAAFSDRLC
SEQ ID NO:252	CVTDQWGGLYC
SEQ ID NO:253	CVPSGRSPNTC
5 SEQ ID NO:254	CPKWSDKRPQC
SEQ ID NO:255	CAPPGIAVRTC
SEQ ID NO:256	CMKWPNSHSC
SEQ ID NO:257	CLQDRAGGYLC
SEQ ID NO:258	CGRLEGRCSHAC
10 SEQ ID NO:259	CYFIAKHGWAC
SEQ ID NO:260	CPPRSSRGFLC
SEQ ID NO:261	CTGISTGEYLC
SEQ ID NO:262	CGPVFYATGLC
SEQ ID NO:263	CLSQYADWTYC
15 SEQ ID NO:264	CARWYPISQTC
SEQ ID NO:265	CQGFPGAPQDC
SEQ ID NO:266	CWHRPTFPATC
SEQ ID NO:267	CTRPPFDPPAC
SEQ ID NO:268	CASPLGPCFWC
20 SEQ ID NO:269	CWTDTYGDLLC
SEQ ID NO:270	CISAGPESSH
SEQ ID NO:271	CHSVQPATRAC
SEQ ID NO:272	CPKAPFSPFKC
SEQ ID NO:273	CIDAGSHGWLC
25 SEQ ID NO:274	CRRGSPLSRYC
SEQ ID NO:275	CSWDEIIDLGC
SEQ ID NO:276	CRSPAGEWSSC
SEQ ID NO:277	CAYHVLRY SAC
SEQ ID NO:278	CAKTVRGDDYYC
30 SEQ ID NO:279	CLAASADTAAC
SEQ ID NO:280	CPYTSWAREGC
SEQ ID NO:289	PPPWSTHD
SEQ ID NO:290	SEPWSTSN
SEQ ID NO:291	AITGVRARW
35 SEQ ID NO:292	EKKHFNYGT
SEQ ID NO:293	EKKRFESNT
SEQ ID NO:294	EQGYCTVNEQCAKYR
SEQ ID NO:295	SPADCDYTTLCAKPT
SEQ ID NO:296	NSPTSCKWLCNEKF
40 SEQ ID NO:297	CPPPWSTHDC
SEQ ID NO:298	CSEPWSTSNC
SEQ ID NO:299	CAITGVRARWC
SEQ ID NO:300	CEKKHFNYGTC
SEQ ID NO:301	CEKKRFESNTC

SEQ ID NO:281 Sequence of the light chain of the H44/24 monoclonal antibody

5 ' GACCCAGTTCCACTTTCCCTGCCTGTCAGTCTGGAGATCAAACCTCCATCTTGCACATCTA
 GTCGGAGCCTTGACACCGTAAAGGAAACACTATTTACATTTGATACCTTCAAGGCAGGCGACTC
 TCCAAAGCTCTGATCTCAAAGTTCACCGATTTCTGGGGTCCAGACAGGTCACTGGCAGTG
 GATCAGGACAGTACCTACAGCATCAGCAGACTGGAGGCTGAGGATCTGGGACTTTATTCCTG
 TCTCAAGTACACATTTCCGTGGAGCTGGGGAGGACCAACCTGAAATCAAACGGGCTGAGTC
 TGCACCAACTGTATCCATCTCCACCATCAGTGGAGCAGTTAACATCTGGAGGTGCTCAGTCGTG
 GCTTCTGAGTCAACTACCCAAAAGCATTAAGTCAAGTGAAGATTGATGGCAGTGAACGACAA
 AAAGGGCTCTGAACAGTGGACTGATCAGGACAGAACAGCACCTACAGCATGAGCAGCACCT
 CACGGTGAACAGGACGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAAGACATCAA
 CCTCACCAATTGTCAAGAGCG 3 '

15 SEQ ID NO:282 Sequence of the heavy chain of the H44/24 monoclonal antibody

5 ' CCTGAGTCTGAAGGTTGCCCTGGTCAGCGTCAGAGGATCCCTGAAACtCTCTGTGCAAGCTCGGA
 TTGATTAGTAGATCTGGATGAGTTGGCTCGGCAAGGCTCCAGGGAAAGGGCTAGAAATGGATTTGG
 AGAAAATTATCCAGATAGCAGAACGATAAACATACGCCTTCTCAAAGGATAATTCACTCATCTCA
 AGAGAACACAGGAGATACCTACGGCTTACGCTTACGAAATGAGCAAATGGAGATCTGAGGGACACAGGCCCTTAT
 TACTGTGCAATCTACTTTACTACGAGCTGGGGTATGGACTGAGCTTACGGGGTCAAGGAACCTCAGTCAC
 CGTCTCTCAGCTACAAACACAGGCCCCATCTGTCTACCTGGCTGGCTGAGTACACATCTG
 GATCCTGGTACAGGACAGTGGATGCTTGTCAAAGGGTACTCTGGCTGGCTGGCTGAGTACATGTAATGGAGAC
 25 TATGGAGGCCCTGTGTCAGCGGCTGGCCACAGCTCATCTGGCTGAGTCTGGGTTCTATTCCCTCAG
 CAGCTGGTACTGATCCTCCAGCACCTGGGCCACGGCAGACTGTCTGCAAGTGTAGGCCACCCAG
 CCAGCAAGACTGAGTTgTCAAGA 3 '

30 SEQ ID NO:283 Sequence of the light chain of the H44/58 monoclonal antibody

5 ' CCCAGTTCCACTTCTCTGCCTGTCAGTCTGGAGATCAAACGCCATCTTGCAGATCTAGTCAG
 AGCTCTGTTCAAAATAAGGAAACACTATTTACATTTGATCTGGGAGCCAGGGCAGTCTCAA
 GCTCTGATCTACAAAGTTCACCGATTCTGGGGTCCCTGAGGTTCTAGTGGCAGTATTCTAG
 GGACAGATTTCACACTCAGGATCAGCAGAGTGGAGGCTGAGGATCTGGAGGTTTATTCCTGCTCTCAA
 35 AGTACACATGTTCTGGAGCTGGAGCTGGGGAGGCCAACAGGAAATCAAACAGGGCTGATGCTGCACC
 AACTGTATCATCTTCCCACCATTCAGTGGAGCTTACATCTGGAGGTGCTCAGTGTGCTCT
 TGAAACACTTCTACCCAAAGACATCAATGTCAGTGGAGATTGATGGCAGTGAACGACAAAATGGC
 GTCTGAGCAGTGGACTGATCAGGACACAAAGACAGCACCTACAGCATGAGCAGCACCTCACCT
 GACCAAGGAGGAGTATGAACGACATAACAGCTATACCTGTGAGGCCACTCACAAAGACATCAACTTCAC
 CCATTGTCAAGAGCG 3 '

40 SEQ ID NO:284 Sequence of the heavy chain of the H44/58 monoclonal antibody

45 5 ' TCTGAGTGGCTGGTGAGCTGAAAGGATCCCTGAAACtCTCTGTGTCGCCACAGGATTGAGATTT
 AGTAGATACTGGATGAGTTGGTCCGGCAGGCTCCAGGGAAAGGGCTAGAGTGGATTGGAGAAATTAA
 TCCAGATAGCAGGAAGATAAACATACGCCATCTCAAAGGATAATTGATCTCATCTCCAGAGACAAAG
 CCAAAATGGTACCGTAAAGGAGTAAAGGAGTCAAGGAGATCTGAGGAGCACAGGCCCTTATTCCTGCA
 GTCTACTATACCTGGAGCTCTGGGATCTGGGACTCTGGGCTAGGAGAACCTCAGTCACCGCTCTC
 50 AGCTCACAAACAGGCCCATCTGTCTATCTCTGGGCTCTGGCTGAGTGGCAGTACATCTGGATCTCGG
 TGAGCATGGGATGCTTGTCAAAGGGTACTCTCCCTGAGCGGTTAAGTGTAAATGGAACTATGGAGCC
 CTGTCAGCGGTTGAGCTCTGAGCTACATCTGTCAGTCTGGGTTATTCCTCAGCAGCTTGT
 GACTGTACCCCTCCAGCACCTGGGCCAGGCCAGACTGTCTGCAAGTGTAGGCCACCCAGGAGCAAGA
 CTGAGTNATCAAGAG 3 '

SEQ ID NO:285 Sequence of the light chain of the H44/70 monoclonal antibody

5 ' TGACCCAGTCTCCACTCACTTTGTGGTGTACCATGGGCAACCCAGCcTCCATcTCTTGCAAGTCA
 AGTCAGAGCCCTTATGAGATGGAAAGACATATTGAAATTGGTTGTTACAGAGGCCAGGCAGTC
 5 TCCAAAGGCCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTCACTGGCAGTG
 GATCAGGGACAGATTCCACACTGAAAATCAGCAGAGTGGAGGCTGAGGATTGGAGTTTATGTC
 TGGCAAGGTACACATTTCTCTCACGTTGGTGTGGGACCAAGCTGGAGCTGAAACGGGTGATGC
 TGCACCAACTGTATCCATCTTCCACCATCAGGTTAACATCTGGAGGTGCTCAGTCAGTGT
 10 GCTCTTGTGAAACACTCTACCCCCAACAGCATCAATGTCAGTGGAAAGATTGATGGCAGTGAACGACAA
 AATGGCGCTCTGAAACAGTGGACTGTACGGACAGCAGAACAGCACCTACAGCATGACGACACCT
 CACGTTGACCAAGGACGAGTATGAAACATAACAGCTACCTGTGAGGCCACTCACAAAGACATCAA
 CTTCAACCATGGTCAAGAGCG 3 '

SEQ ID NO:286 Sequence of the heavy chain of the H44/70 monoclonal antibody

5 ' ACAGGTAAGCTGGGCTTCACTGGAGGATATCCTGTAAGGTTGcTGGcTACACCTTCACAGCTAC
 TATATACACTGGGTAAGCAGAGGCCCTGGACAGGGACTTGAGTGGATGGATTTATCCTGGAAA
 20 TGTAACTACTAACTGAGAGTCTCAAGGGCAAGGCCACACTGACTGAGAACAAATCCTCAGCA
 CAGCCTACATCAGCTCACGAGCCGCTGACCTCTGAGGACTCTCGCGTCTATTTCTGTCAGAGGGGG
 GTACGGTATGCTATGGACTACTGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGAGTCACTGCTT
 CCCAAATGTCCTCCCGTCTCTGGAGGAGGCCCTGCTGATAAGAACTCTGGCCATGGGCT
 25 GCCTGGCCGGGACTCTGGCCACGACCTTCTCCTCCTGGAAACTACCRGAACAAACTGAAAGTC
 ATCCAGGGTATGAAACACTTCCACACTGAGGACAGGGGCAAGTACCTGACCCACCTCGCAGGTT
 GCTGTCCTCAAGAGCATCTTGAAGGTTAGATGAATACCTGGTATGCAAAATCCTACAGGAGGA
 AAAACAGAG 3 '

SEQ ID NO:287 Sequence of the light chain of the H44/78 monoclonal antibody

30 5 ' CTGACCCAGTCCACTCACTTGTGCTGGTACCATGGGCAACCCAGCcTCCATcTCTTGCAAGTCAA
 GTCAAGGcTCTTAGATGATGGAAAGACATATTGAAATTGGTTGTTACAGAGGCCAGGCAGCT
 CCAAAGGCCCTAATCTATCTGGTGTCTAACTGGACTCTGGAGTCCCTGACAGGTTCACTGGCAGTG
 ATCAGGGACAGATTTCACACTGAGAGTGGAGGCTGAGGATTGGAGTTTATTTATGCT
 35 GGCAGGTACACATTTCGCTCACGTTGGTGTGGGACCAAGCTGGAGCTGAAACGGGTGATGCT
 GCACCAACTGTATCCATCTCCACCATCAGTGGAGCAGCTAACATCTGGAGGTGCTCAGTCGTG
 CTTCTGGACAACTCTACCCCCAAAGACATCAAACTGAGTGGAGGATGTAGTGGCAGTGAACGACAAA
 ATGGCGCTCTGAAACAGTGGACTGTACGGAGAACAGCACCTACAGCATGAGCAGCACCCCTC
 ACGGTGGACCAAGGAGCAGTATGAACGACATAACAGCTAACCTGTGAGGCCACTCACAGACATCAAC
 40 TTCAACCATGGTCAAGAGCG 3 '

SEQ ID NO:288 Sequence of the heavy chain of the H44/78 monoclonal antibody

45 5 ' GTCTGGACCTAAAGTGGTAAAGCTGGGCTTCACTGGAGGATATCCTGCAAGGCTCTGGcTACAC
 TTCAACAGCTACTATATACACTGGGTGAAGCAGAGGCCCTGGACAGGGACTTGAGTGGATGGAT
 TTATCTGGAAATGTTAACTACTAAAGTACAAATGAGAAGTTCAGGGCAAGGCCACACTGACTGCAAGACA
 AATCTTCCAGCACAGCCATCTGAGCTCACGAGCTGACCTCTGAGGACTCTGGGTCTATTCTGT
 GCAAGATCTACTACGGCTAGGGGACTTTGACTACTGGGCAAGGCCACACTCACAGTCTCTC
 AGAGAGTCACTGGGCTAGGGGACTTTGACTACTGGGCAAGGCCACACTCACAGTCTCTC
 50 TGGTGGCCATGGGCTGCTGGCCCGGACTCTGCCCCAGACCATTTCTCACCTGGAACTACCCAG
 AACAAACACTGAGGTCATCCACGGGTATCAGAAACCTTCCAAACACTGAGGACAGGGGCAAGTACCTAGC
 CACCTCCAGGTGTTGCTCTCCAAAGAGCATCTTGAAGGTTAGATGAATACCTGGTATGCAAAA
 TCCACTACGGAGGCAAAACAGAG 3 '

Applicant's or agent's file B45342 reference number	International application No.
--	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page 11 lines 8-17 and page 15 lines 5-9.	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution European Collection Of Cell Cultures	
Address of depositary institution (<i>including postal code and country</i>) Vaccine Research And Production Laboratory, Public Health Laboratory Service, Centre for Applied Microbiology Research, Porton Down, Salisbury, Wiltshire SP4 0JG, GB	
Date of deposit: 22/09/00 (22 September 2000)	Accession Number 92209, 92210, 92211 and 92212
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>) This information is continued on an additional sheet <input type="checkbox"/> In respect of those designations where a European Patent is sought, a sample of the deposited microorganisms will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (<i>if the indications are not for all designated States</i>)	
E. SEPARATE FURNISHING OF INDICATIONS (<i>leave blank if not applicable</i>) The indications listed below will be submitted to the International Bureau later (<i>specify the general nature of the indications e.g., "Accession Number of Deposit"</i>)	

For receiving Office use only		For International Bureau use only		
<input type="checkbox"/>	This sheet was received with the international application			
Authorized officer		<input type="checkbox"/>	This sheet was received by the International Bureau on:	
				Authorized officer

We Claim:

1. A mimotope of a surface L3,7,9 LOS of *N. meningitidis*, said mimotope comprising a peptide epitope obtainable by screening a peptide library with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78.
2. A mimotope of a surface L3,7,9 LOS of *N. meningitidis*, said mimotope being antigenically cross-reactive with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78.
3. The mimotope according to claim 1 or claim 2, which comprises a peptide epitope contained within any one of the peptides of SEQ ID NO: 1-140, 289-296, or retro sequences thereof.
4. The mimotope according to claim 3, wherein the peptide epitope is present in a nonapeptide.
5. The mimotope according to claims 3-4, which comprises any one of the peptides of SEQ ID NO: 1-140, 289-296, or retro sequences thereof, or modifications of the peptides or retro sequences which retain cross-reactivity with a monoclonal antibody selected from a group consisting of: 4BE12C10; H44/24; H44/58; H44/70; and H44/78.
6. The mimotope of claims 3-5, wherein the peptide epitope comprises the amino acid sequence PP[Y or F or W]D.
7. The mimotope of claim 6, wherein the peptide epitope comprises the amino acid sequence PP[Y or F or W]D.
8. The mimotope of claim 7, wherein the peptide epitope comprises the amino acid sequence PPYD.

9. The mimotope of claims 3-5, wherein the peptide epitope comprises the amino acid sequence WY.

10. The mimotope of claim 9, wherein the peptide epitope comprises the amino acid sequence WYXXP.

11. The mimotope of claims 3-5, wherein the peptide epitope comprises the amino acid sequence [Y or W]XY.

10 12. The mimotope of claims 3-11, wherein said mimotope comprises an oligopeptide, comprising said peptide epitope, which is structurally more constrained than an unsubstituted linear form of the oligopeptide.

15 13. The mimotope according to claim 12, wherein the oligopeptide comprises a cyclic peptide encompassing the peptide epitope.

14. The mimotope according to claim 13, wherein the cyclic peptide comprises a cyclised portion which comprises an amino acid sequence, the terminal amino acids of which are linked together by a covalent bond.

20 15. The mimotope according to claim 14, wherein the cyclic peptide is any one of the peptides of SEQ ID NO: 141-280, 297-301, or retro sequences thereof.

25 16. The mimotope according to any one of the preceding claims, wherein a carrier is conjugated to the mimotope to enhance the immunogenicity thereof.

17. The mimotope according to claim 16, wherein the carrier comprises an immunogenic protein.

30 18. A vaccine comprising a mimotope according to any one of the preceding claims and a suitable excipient or diluent.

19. A vaccine against serogroup B, C, Y, or W-135 meningococci, which comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis* and a mimotope of a surface L2 LOS of *N. meningitidis*.

5 20. The vaccine according to claim 19, wherein the mimotopes are antigenically cross-reactive with a monoclonal antibody of high specificity to the respective surface LOS.

10 21. The vaccine according to claim 19 or claim 20, wherein the mimotopes each comprise a peptide epitope.

22. The vaccine according to claim 21, wherein the peptide epitopes are obtainable by screening a peptide library with the respective monoclonal antibodies of claim 20.

15 23. The vaccine of claim 21 or 22, wherein the L3,7,9 and the L2 mimotopes are contained within the same molecule.

20 24. The vaccine according to claims 21-23, wherein the mimotope of a surface L3,7,9 LOS is the mimotope of claims 2-17.

25 25. The vaccine according to claims 21-23, wherein the mimotope of a surface L3,7,9 LOS comprises a peptide selected from:

IHRQGIH; HIGQRHI; LPARTEG; GETRAPL; APARQLP; PLQRAPA; KQAPVHH; HHVPAQK; LQAPVHH; HHVPAQL; LPSIQLP; PLQISPL; NELPHKL; LKHPLEN; KSPSMTL; LTMSPSK; AGPLMLL; LLMLPGA; WSPILLD DLLIPSW; LSMHPQN; NQPHMSL; HSMHPQN NQPHMSH; SMYGGSYN; NYSGYMS; TNHSLYH; HYLSHNT; HAIYPRH; HRPYIAH; TTYSRFP; PFRSYTT; TDSLRLL; LLRLSDT; SFATNIP; and PINTAFS.

30 26. The vaccine according to claim 19-25, wherein the mimotope of a surface L2 LOS is antigenically cross-reactive with F1-5H 5/ID9 monoclonal antibody.

27. A vaccine against serogroup A meningococci, which comprises a mimotope of a surface L3,7,9 LOS of *N. meningitidis* and a mimotope of a surface L10 LOS of *N. meningitidis*.

5 28. The vaccine according to claim 27, wherein the mimotope of a surface L10 LOS is antigenically cross-reactive with a monoclonal antibody of high specificity to the L10 LOS.

10 29. The vaccine according to claim 28, wherein the monoclonal antibody is 5B4-F9-B10.

30. The vaccine of claim 28 or 29, wherein the mimotope of a surface L10 LOS comprises a peptide epitope.

15 31. A meningococcal vaccine comprising a mimotope of a surface L3,7,9 LOS of *N. meningitidis*, a mimotope of a surface L10 LOS of *N. meningitidis*, and a mimotope of a surface L2 LOS of *N. meningitidis*.

20 32. A meningitis vaccine comprising the vaccine of claim 31, and a conjugated *H. influenzae* b capsular polysaccharide.

33. A H44/24 hybridoma deposited under the Budapest Treaty patent deposit at ECACC on 22/9/00 with Provisional Accession Number 92209.

25 34. A H44/58 hybridoma deposited under the Budapest Treaty patent deposit at ECACC on 22/9/00 with Provisional Accession Number 92210.

35. A H44/70 hybridoma deposited under the Budapest Treaty patent deposit at ECACC on 22/9/00 with Provisional Accession Number 92211.

30

36. A H44/78 hybridoma deposited under the Budapest Treaty patent deposit at ECACC on 22/9/00 with Provisional Accession Number 92212.

37. A monoclonal antibody obtainable from any of the hybridomas of claims 33-36.

38. Use of the monoclonal antibodies of claim 37 in the identification of mimotopes of *N. meningitidis* L3,7,9 LOS.

39. A pharmaceutical composition comprising the monoclonal antibody of claim 37.

10 40. A mimotope as described in claims 1-17, or a vaccine as described in claims 18-32, or a monoclonal antibody as described in claim 37 for use as a medicament.

15 41. Use of the mimotope of claims 1-17, or the vaccine of claims 18-32, or the monoclonal antibody of claim 37 in the manufacture of a medicament for the treatment or prevention of meningococcal disease.

20 42. A method of manufacturing a vaccine comprising the manufacture of a mimotope as claimed in any one of claims 1 to 17, and formulating the mimotope with an adjuvant.

43. A method for treating a patient suffering from or susceptible to meningococcal disease, comprising the administration of the mimotope of claims 1-17, or the vaccine of claims 18-32, or the monoclonal antibody of claim 37, to the patient.

25 44. A DNA sequence encoding the mimotope of claims 1-16.

45. A diagnostic assay for meningococcal infection comprising the use of the mimotope of claims 1-16 to detect antibodies against L3,7,9 LOS in the serum of a patient.

30 46. A diagnostic assay for meningococcal infection comprising the use of the monoclonal antibody of claim 37 to detect the presence of L3,7,9 immunotype meningococcus in a sample from a patient.

47. A DNA sequence encoding a CDR region encoded by the DNA sequences of SEQ ID NO:281-288.